Archive for February, 2015

(CERU) 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer

Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, announced today that preclinical data for CRLX101 as monotherapy and in combination with Avastin® have been selected to be the subject of an oral presentation at the 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer to be held February 19-21, 2015 in San Diego, California.

Elizabeth Pham, Ph.D., Postdoctoral Fellow, Sunnybrook Research Institute in Toronto, will discuss the results of preclinical mouse models of advanced metastatic cancer in an abstract presentation titled Translational evaluation of the investigational nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian and breast cancer, as part of a session on biomarkers on Friday, February 20, 1:25 p.m. PT. The ovarian data were the subject of a manuscript published in Clinical Cancer Research.

In an ovarian cancer model, CRLX101 monotherapy was highly efficacious, and chronic low-dose CRLX101 with Avastin reduced HIF-1α up-regulation and resulted in synergistic efficacy, with minimal toxicity in mice. In breast cancer models in mice, CRLX101 monotherapy was highly efficacious, and CRLX101 with Avastin resulted in dramatic, durable primary tumor shrinkages and greatly improved survival.

“These data support a growing view in the anti-angiogenesis community that adding a durable HIF-inhibitor like CRLX101 to VEGF inhibitors, which drive up HIF, could lead to important benefits for patients,” said Elizabeth Pham, Ph.D.

Elizabeth Pham is a Postdoctoral Fellow in the lab of Robert S. Kerbel, Ph.D., Sunnybrook Research Institute, who serves as a Chair and on the selection committee for the Symposium on Anti-Angiogenesis and Immune Therapies for Cancer. Dr. Kerbel recused himself from the scoring for this abstract due to his affiliation with the research.

About CRLX101

CRLX101 is a dynamically tumor-targeted nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload, camptothecin, inside tumor cells. CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and hypoxia-inducible factor-1α (HIF-1α), which research suggests is a master regulator of cancer cell survival mechanisms thought to promote drug and radiation resistance. CRLX101 has shown activity in four different tumor types, both as monotherapy and in combination with other cancer treatments. CRLX101 is currently in Phase 2 clinical development and has been dosed in more than 250 patients.

About CRLX301

CRLX301 is a dynamically tumor-targeted NDC designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells. In preclinical studies, CRLX301 delivers up to 10 times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available docetaxel and was superior to docetaxel in seven of seven animal models, with a statistically significant survival benefit seen in five of those seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported with docetaxel in similar preclinical studies. CRLX301 is currently in Phase 1 clinical development.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit www.ceruleanrx.com.

About Cerulean’s Dynamic Tumor Targeting Platform

Cerulean’s Dynamic Tumor Targeting Platform creates NDCs that are designed to provide safer and more effective cancer treatments. We believe our NDCs concentrate their anti-cancer payloads inside tumors while sparing normal tissue because they are small enough to pass through the “leaky” vasculature present in tumors but are too large to pass through the wall of healthy blood vessels. Once inside tumors, our NDCs enter tumor cells where they slowly release anti-cancer payloads from within the tumor cells.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, statements about our estimated research and development expenses and sufficiency of cash to fund specified use of cash and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2014 and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Avastin® is a trademark of Genentech Inc.

Cerulean Pharma Inc.
Aurora Krause, 617-551-9627
Corporate Communications
ir@ceruleanrx.com

Thursday, February 19th, 2015 Uncategorized Comments Off on (CERU) 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer

(PEGA) Appoints Kelly Hicks as CFO

Veteran Financial Executive to Help Facilitate Aryaka’s Rapid Global Growth and Expansion

MILPITAS, CA–(Feb 19, 2015) – Aryaka®, the leading ‘As-A-Service’ provider of WAN Optimization, Network, Application Delivery and Cloud Networks, announced today that Kelly Hicks will join the company’s leadership team as Chief Financial Officer. Reporting to Aryaka president and CEO Ajit Gupta, Hicks will be charged with building out world-class finance and administrative functions to help lead and provide the scale needed to support Aryaka’s rapid global growth.

Mr. Hicks brings over twenty-five years business and financial leadership experience, including CFO roles at global public and private companies in the software and hardware technology sectors. His expertise includes scaling rapid-growth businesses, leading strategic acquisitions, securing equity and debt financing, and transitioning businesses from private to public entities.

“Kelly Hicks is an accomplished financial and operational executive with significant expertise in the technology space, and with fast-growth companies like Aryaka,” said Ajit Gupta, president and CEO of Aryaka. “He is an important and highly valued addition to our leadership team. Financial and operational excellence is critical as we accelerate global growth and embark on the next stage of our business expansion.”

Prior to joining Aryaka, Mr. Hicks was Head of Corporate Finance at Atlona, Inc., where he led finance and operational functions to deliver record revenues and profit for the company. As Vice President of Worldwide Field Operations at Chordiant Software, he provided leadership guidance during a rapid growth phase prior to its sale to Pegasystems (NASDAQ: PEGA). As CFO at Tahoe Networks, he was instrumental to its sale to Nokia (NYSE: NOK). Mr. Hicks also held senior financial positions with Puma, Inc. (NASDAQ: PUMA) and The Santa Cruz Operation, Inc. (NASDAQ: SCOC) during both companies’ successful IPOs.

Hicks holds a Bachelor of Business Administration Degree with a concentration in Finance from California State University, Chico.

About Aryaka
Aryaka is the world’s first and only global, private, optimized, secure and on demand network that delivers simplicity and agility to address all enterprise connectivity and application performance needs for better collaboration, communication and business productivity. Aryaka eliminates the need for costly WAN appliances or long-haul private MPLS links. Aryaka’s premier WAN Optimization as-a-Service accelerates any application to any location on one optimized network. Aryaka’s Network as-a-Service provides organizations an optimized network with QoS for instant and reliable business connectivity. Aryaka’s Network OnDemand provides organizations with flexibility, agility, connectivity and optimization worldwide. Aryaka’s Cloud Network as-a-Service provides organizations an optimized and fully meshed network to cloud services. Aryaka’s Application Delivery as-a-Service enables distributed business users to quickly access centralized enterprise applications and Cloud resources from anywhere in the world over a private CDN built for the enterprise. All services provide end-to-end visibility with 24×7 world-class support. To learn more, visit www.aryaka.com. Follow us on Twitter, Facebook, YouTube and LinkedIn.

Contact:

Aaron Murphy
Horn Group
Email Contact
415-905-4019

Thursday, February 19th, 2015 Uncategorized Comments Off on (PEGA) Appoints Kelly Hicks as CFO

(ORMP) to Present Poster at the GTC Protease Inhibitors in Drug Discovery Conference

JERUSALEM, February 19, 2015  —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract titled “Protease Inhibitor Support in Oral Insulin Delivery” will be presented in poster sessions at the GTC Protease Inhibitors in Drug Discovery Conference on February 26-27, 2015 in San Diego. The poster will be attended by Oramed’s Chief Scientific Officer, Dr. Miriam Kidron.

About Protease Inhibitors in Drug Discovery Conference

The meeting will provide a forum for scientists from both industry and academia to share recent advances in protease inhibitor research, from biological functions to translational aspects for drug discovery.

For more information on the conference please visit https://www.gtcbio.com/conferences/protease-inhibitors-drug-discovery-overview

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration.  In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact
Oramed Pharmaceuticals
Ariella Vaystooch
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com

Thursday, February 19th, 2015 Uncategorized Comments Off on (ORMP) to Present Poster at the GTC Protease Inhibitors in Drug Discovery Conference

(VHC) Denial of Five (AAPL) Petitions for Inter Partes Review of VirnetX Patents

Apple Previously Found to Infringe the Patents-at-Issue

ZEPHYR COVE, Nev., Feb. 18, 2015  — VirnetX™ Holding Corporation (NYSE MKT: VHC), an Internet security software and technology company, announced today that on February 17, 2015,  the Patent Trial and Appeal Board (PTAB or Board) of the United States Patent and Trademark Office (USPTO) denied five petitions for inter partes review (IPR) filed by Apple Inc. These petitions sought review of certain claims of three of VirnetX’s U.S. Patent Nos. 7,921,211 (‘211 patent), 7,418,504 (‘504 patent) and 7,491,151 (‘151 patent).  For all five petitions, the Board determined that they were not filed within the time limit imposed by the statute and declined to institute IPRs. In the same order, the Board also dismissed Apple’s request to join the IPRs previously filed by Microsoft, as those IPRs had already been terminated.

Apple was found to infringe the ‘211, ‘504 and ‘181 patents in a lawsuit filed by VirnetX against Apple. The United States Court of Appeals for the Federal Circuit also affirmed the validity of the claims-at-issue of these three patents in its decision on September 16, 2014.

“We are pleased with the PTAB’s decisions to deny Apple’s petitions,” said Kendall Larsen, VirnetX CEO and President. “With these latest decisions, the USPTO has now either declined to institute review or terminated 37 IPR proceedings that were filed by New Bay, Apple, RPX, and Microsoft.”

About VirnetX
VirnetX Holding Corporation is an Internet security software and technology company with patented technology for secure communications including 4G LTE security.  The Company’s software and technology solutions, including its secure domain name registry and GABRIEL Connection Technology™, are designed to facilitate secure communications and to create a secure environment for real-time communication applications such as instant messaging, VoIP, smartphones, eReaders and video conferencing.  The Company’s patent portfolio includes over 107 U.S. and international patents with over 100 pending applications.  For more information, please visit www.virnetx.com.

Forward Looking Statements
Statements in this press release that are not statements of historical or current fact, including statements regarding the  strength of Virnetx’s intellectual property, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are based on expectations, estimates and projections about the markets in which the Company operates, management’s beliefs, and certain assumptions made by management and involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements, including but not limited to (1) the outcome of any legal proceedings that have been or may be initiated by the Company or that may be initiated against the Company, including pending and future inter partes review proceedings in the Patent and Trademark Office; (2) the ability to capitalize on the Company’s patent portfolio and generate licensing fees and revenues; (3) the ability of the Company to be successful in entering into licensing relationships with its targeted customers on commercially acceptable terms; (4) potential challenges to the validity of the Company’s patents underlying its licensing opportunities; (5) the ability of the Company to achieve widespread customer adoption of the Company’s GABRIEL Communication Technology™ and its secure domain name registry; (6) the level of adoption of the 3GPP Series 33 security specifications; (7) whether or not the Company’s patents or patent applications may be determined to be or become essential to any standards or specifications in the 3GPP LTE, SAE project or otherwise; (8) the extent to which specifications relating to any of the Company’s patents or patent applications may be adopted as a final standard, if at all; and (9) the possibility that Company may be adversely affected by other economic, business, and/or competitive factors.  In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” or “plans” to be uncertain and forward-looking.  The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading “Risk Factors” in Company’s Quarterly Report on Form 10-Q filed with the SEC on November 10, 2014.  Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s ability to control or predict.  Except as required by law, the Company is under no duty to update any of the forward-looking statements after the date of this press release to conform to actual results.

Contact:
Greg Wood
VirnetX Holding Corporation
775.548.1785
greg_wood@virnetx.com

Wednesday, February 18th, 2015 Uncategorized Comments Off on (VHC) Denial of Five (AAPL) Petitions for Inter Partes Review of VirnetX Patents

(PLPM) Pay in Your Currency(R) Assists Merchants in Offsetting Cost of EMV Migration

LONG BEACH, N.Y., Feb. 18, 2015  — Planet Payment, Inc. (Nasdaq:PLPM), a leading provider of international and multi-currency payment processing services, is promoting its Pay in Your Currency solution as a way for US merchants to help offset the expense of upgrading their point-of-sale systems for EMV acceptance while also providing their international customers with enhanced customer service.

In October 2015, the Payments Networks’ Liability Shift will take effect in the United States, making any merchant using non-EMV compatible devices liable for most fraud involving EMV cards. According to Javelin Strategy & Research, the U.S. has been lagging in the adoption of EMV technology, with only 10% of terminals and less than 1% of cards EMV-enabled today, compared to 76% of terminals and 45% of cards globally.1 One of the key reasons behind this slow adoption is believed to be the cost – it is estimated that merchants will need to spend $2.6 billion for upgrades to EMV-enabled POS hardware.2

Planet Payment believes that Pay in Your Currency can help reduce the cost barrier that may be preventing many merchants from making the shift to EMV-enabled POS solutions. With Pay in Your Currency, merchants offer international cardholders the choice to pay using eligible MasterCard and Visa cards in the currency they know best – their own. Pay in Your Currency can also reduce the cost of international card acceptance, and merchants can use the funds saved to offset the expense of their EMV hardware upgrade. Today, with most international cards being EMV-enabled, Pay in Your Currency is a natural complement to a merchant’s EMV strategy.

As an international payment processor, Planet Payment has been EMV ready in the United States since 2013 and has experience processing EMV card transactions in 20 countries across North America, Asia Pacific and the CEMEA regions. Planet Payment’s Pay in Your Currency solution is available through several of the leading acquirers and processors in the United States.

“With the upcoming liability shift, now is the time when many merchants are considering their plans to upgrade their point-of-sale systems to support EMV,” said Carl Williams, Chairman and CEO of Planet Payment, “This is an ideal time to incorporate Pay in Your Currency into their card acceptance offering, allowing merchants to provide their international customers with greater convenience, while helping to offset the cost of their EMV POS upgrades.”

About Planet Payment

Planet Payment is a leading provider of international payment processing and multi-currency processing services. We provide our services in 23 countries and territories across the Asia Pacific region, North America, the Middle East, Africa and Europe, primarily through our 70 acquiring bank and processor customers. Our point-of-sale and e-commerce services help merchants sell more goods and services to consumers, and together with our ATM services are integrated within the payment card transaction flow enabling our acquiring customers, their merchants and consumers to shop, pay, transact and reconcile payment transactions in multiple currencies, geographies and channels.

Planet Payment is headquartered in New York and has offices in Atlanta, Beijing, Bermuda, Delaware, Dubai, Dublin, London, Hong Kong, Mexico City, Shanghai and Singapore. Visit www.planetpayment.com for more information about the Company and its services.

1. https://www.javelinstrategy.com/news/1360/92/1

2. EMV IN USA: Assessment of Merchant and Card Issuer Readiness. Javelin Strategy and Research, April 2014

CONTACT: Planet Payment
         Contact: Jill Raftery
         Telephone: 516.941.1858
         email: jraftery@PlanetPayment.com
         www.PlanetPayment.com
Wednesday, February 18th, 2015 Uncategorized Comments Off on (PLPM) Pay in Your Currency(R) Assists Merchants in Offsetting Cost of EMV Migration

(HTBX) & (ONCS) Collaboration to Evaluate Combination of Immunotherapy Platforms

OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, and Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.

Under the agreement, OncoSec and Heat will jointly evaluate the preclinical efficacy of OncoSec’s core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform, with Heat’s proprietary gp-96-Ig based ImPACT immunotherapy platform.

“We are excited to initiate this collaboration with OncoSec, one of the leaders in the field of intratumoral DNA delivery,” said Taylor Schreiber, MD, PhD, Heat’s Vice President of Research and Development. “This collaboration with OncoSec reflects our desire to expand Heat’s ImPACT platform into DNA-based immunotherapies to stimulate immunity to both shared and private tumor antigens without introducing the complexities associated with personalized therapies,” Dr. Schreiber added.

“In this collaboration we will evaluate the efficacy of Heat’s proprietary DNA constructs with OncoSec’s clinical stage electroporation platform,” said Robert H. Pierce, MD, OncoSec’s Chief Scientific Officer. “Heat’s ImPACT platform is a unique approach that specifically activates tumor specific cytotoxic T-cells. We expect it will be effective with OncoSec’s proprietary intratumoral delivery platform that has already shown promising clinical activity in both local and distant tumors in patients with metastatic melanoma,” Dr. Pierce stated.

OncoSec and Heat are exploring this combination as part of their ongoing strategy to expand the application of their technologies to benefit cancer patients with unmet medical needs. OncoSec’s core platform, ImmunoPulse, which is based on the intratumoral delivery of DNA IL-12, is currently in Phase 2 clinical trials, investigating the approach for treatment of metastatic melanoma, head and neck cancer, triple negative breast cancer, and cutaneous T-cell lymphoma. Heat has two clinical stage programs based on the ImPACT platform, viagenpumatucel-L (HS-110) in a Phase 2 clinical trial in patients with non-small cell lung cancer and vesigenurtacel-L (HS-410) in a Phase 2 clinical trial in patients with non-muscle invasive bladder cancer.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical’s core technology is designed to enhance the local delivery and uptake of plasmid-encoded IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

About Heat Biologics, Inc.

Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, “off-the-shelf” ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to “pump out” a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called “gp96” to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.

OncoSec Medical Inc. Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Heat Biologics, Inc. Forward-Looking Statements

This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for impact of Heat’s ImPACT Therapy, the expectation that Heat’s technology will be effective with OncoSec’s platform. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat’s ImPACT Therapy to perform as designed, the contributions to be derived from the collaboration, the ability of Heat to meet each of its anticipated objectives and to do so on a timely basis and the other factors described in our annual report on Form 10-K for the year ended December 31, 2013 and our other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

OncoSec Medical Inc. Contact Information:
Jordyn Kopin, 855-662-6732
Investor Relations
investors@oncosec.com
or
Mary Marolla, 855-662-6732
Media Relations
media@oncosec.com
or
Heat Biologics, Inc. Contact Information:
Jeff Wolf, Chief Executive Officer
919-240-7133
investorrelations@heatbio.com
or
Investor Relations
LifeSci Advisors LLC
Michael Wood, 646-597-6983
mwood@lifesciadvisors.com

Wednesday, February 18th, 2015 Uncategorized Comments Off on (HTBX) & (ONCS) Collaboration to Evaluate Combination of Immunotherapy Platforms

(ADXS) Completes $23 Million Financing

Institutional Ownership in Advaxis Continues to Increase

PRINCETON, N.J., Feb. 18, 2015  — Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it has executed definitive securities purchase agreements with several institutional investors for gross proceeds of approximately $23.0 million in a registered direct offering of approximately 3.1 million shares at a price of $7.50 per share. The pricing on this transaction reflects the at-the-market closing price on February 17, 2015.

Adage Capital Management, L.P. (“Adage”), Broadfin Capital LLC, Sectoral Asset Management, Cormorant Asset Management and certain funds and accounts managed by T. Rowe Price Associates, Inc. participated in this financing along with another institutional investor. Following the close of the transaction, Adage will own approximately 19% of the outstanding shares of Advaxis. Proceeds from this financing will be used primarily to fund the continued clinical development of Advaxis’s cancer immunotherapy pipeline.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead Lm-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’s ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis’s second Lm-LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. (“Merck”), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm-LLO immunotherapy ADXS-HER2, to target the HER2 receptor expressing cancers. HER2 is expressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-HER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-HER2 for both human and animal-health, and has seen encouraging data in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis has licensed ADXS-HER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

For more information about our cancer immunotherapies please visit www.advaxis.com.

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’s ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis’s proprietary immunotherapies, ADXS-HPV and ADXS-PSA; and initiation of clinical trials in 2015 involving our Lm-LLO immunotherapy platform. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’s SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2014, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

KEYTRUDA is a registered trademark of Merck & Co., Inc.

CONTACT: Company:
         Advaxis, Inc.
         Greg Mayes, Executive Vice President and COO
         mayes@advaxis.com
         609.452.9813 ext. 102

         Media Contact:
         Tiberend Strategic Advisors, Inc.
         Amy S. Wheeler
         awheeler@tiberend.com
         646.362.5750
Wednesday, February 18th, 2015 Uncategorized Comments Off on (ADXS) Completes $23 Million Financing

(NETE) Wins Silver in Best in Biz Awards 2014

Aptito Platform Named 2014’s Most Innovative Product

MIAMI, Feb. 18, 2015  — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a technology-driven group specializing in mobile payments and value-added transactional services in emerging countries and in the United States, announces that its Aptito product was named a silver winner in the Most Innovative Product of the Year – SMB category in Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts.

Aptito’s all-in-one restaurant and bar point-of-sale (POS) and business management software provides restaurants with a variety of tools to reduce payroll costs, improve efficiency, and increase customer satisfaction. The cloud-based, fully integrated solution is based on Apple iOS devices and includes POS and table management, kiosk, digital menu, mobile POS, online ordering modules and integrated payment card processing. Restaurant owners and managers can access the system from any location using any web browser and review comprehensive reports, adjust menus, pricing, set up happy hours, manage inventory, personnel, wages and tips allocation. Aptito’s backend reports are combined with Net Element’s Unified Payments Insights analytics solutions to help owners and managers make educated decisions on how to improve their sales, attract customers during low occupancy hours, and monitor restaurant reputation and social media reviews.

This year’s Best in Biz Awards program featured a large and distinguished judging panel comprised of members of the media who reviewed and scored the hundreds of award nominations. More than 550 award nominations were received this year in a variety of company, executive, team, and product-focused categories. Nominations were fielded from public and private companies of all sizes and from virtually every major industry and region in the United States and Canada.

“The fourth annual Best in Biz Awards’ North American program was its most competitive yet,” says Net Element CEO Oleg Firer. “We are honored that the innovation and functionality of Apito warranted such high recognition among hundreds of other nominees. Bringing home the silver award is a token not only of where Aptito stands today, but of the incredible potential that lies ahead.”

Best in Biz Awards 2014 honors were presented in 60 categories, including Company of the Year, Fastest-Growing Company of the Year, Most Innovative Company of the Year, Best Place to Work, Technology Department of the Year, Executive of the Year, Most Innovative Product of the Year, Best New Product of the Year, PR Campaign of the Year and Website of the Year.

Winners were determined based on scoring from an independent panel of 53 judges from highly recognized newspapers, business, consumer and technology publications, radio outlets, and analyst firms. In addition to returning judges, this year’s 53-person judging panel included contributors to AdWeek, American Banker, Android Central, Atlanta Tribune, Boston.com, Buffalo News, Business News Daily, Chip Design Magazine, Computerworld, Connecting Women Radio, Consumer Affairs, Crain’s New York Business, CRN, Detroit Free Press, Digital Trends, ECT News Network, Entrepreneur, eWeek Channel Insider, Fierce Online Video, IDB Ventures, IEEE Institute, Inc. Magazine, InfoRisk Today, Information Week, Journal Times, King Features Syndicate, L.A. Biz, Lab Reviews, Law Technology News, Marketing Profs, MediaPost, Miami Herald, Motley Fool, New York Observer, NorthBay Biz, PC Magazine, peHUB, Phoenix Business Journal, Quad-City Times, San Jose Mercury News, Silicon Valley Business Journal, Small Business Digest, Tech Cocktail, Tech-Gaming, TheDeal.com, Upstart Business Journal, Venture Capital Journal, Wired, Xconomy and ZDNet.

For a full list of gold, silver and bronze winners in Best in Biz Awards 2014, visit: http://www.bestinbizawards.com/2014-winners.

About Net Element (NASDAQ: NETE)
Net Element (NASDAQ: NETE) is a global technology-driven group specializing in mobile payments and value-added transactional services. The Company owns and operates a global mobile payments and transaction processing provider, TOT Group. TOT Group companies include Unified Payments, recognized by Inc. Magazine as the #1 Fastest Growing Private Company in America in 2012; Aptito, a next generation cloud-based point of sale payments platform; and TOT Money, which has a leading position in Russia and has been ranked as the #1 SMS content provider by Beeline, Russia’s second largest telecommunications operator. Together with its subsidiaries, Net Element enables ecommerce and adds value to mobile commerce environments. Its global development centers and high-level business relationships in the United States, Russia and Commonwealth of Independent States strategically position the Company for continued growth. More information is available at www.netelement.com.

About Best in Biz Awards
Best in Biz Awards recognizes top companies, teams, executives and products for their business success as judged by established members of the press and industry analysts. Best in Biz Awards honors are conferred in two separate programs annually: North America, and International. Entries will begin to be accepted in the Best in Biz Awards 2015 International program in January 2015. Any organization worldwide may participate in the International program in any of the more than 60 company, department or team, executive and product categories. For more information about the entry process and categories in the International program, please visit: http://intl.bestinbizawards.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, whether Net Element or its business continues to grow, whether the award received for the Aptito product will have a positive effect on the Company’s business, whether Net Element can secure any additional financing and if such additional financing will be adequate to meet the Company’s objectives.  All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K and the subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Wednesday, February 18th, 2015 Uncategorized Comments Off on (NETE) Wins Silver in Best in Biz Awards 2014

(ANY) Provides Business Update in Open Letter to Shareholders

SAN JOSE, CA–(Feb 17, 2015) – Sphere 3D Corporation (NASDAQ: ANY), a virtualization and data management solutions provider, today provided a corporate update through an open letter to shareholders.

To our Shareholders, Partners and Customers,

Last year was a transformational year for us and we closed it out with a bang! We took a giant step forward as a company through bold moves designed to provide a solid foundation from which we can launch our many fantastic new products. We closed out 2014 with strong financial results as compared to our prior results, and have started building momentum for 2015.

For fiscal Q4 2014, we expect to exceed revenue projections with a record US$9.0 million (C$10.44 million) for the quarter. As a result of our commitment to operational efficiency, we worked with Overland management, prior to the completion of our acquisition, to ensure that their targeted US$20 million in annualized operating expense reductions were not only met, but were 15% (US$3 million) ahead of expectations. Our annualized revenue run rate has grown from less than US$4 million in Q1 2014 to over US$36 million in Q4 2014, and we have set our goal for an annualized run rate of over US$160 million in Q4 2015.

The founders of the company anticipated that the evolution of technology would see people connecting to their data through an ever increasing variety of devices operating on a wide array of platforms. Today billions of cloud connected devices utilize many diverse operating systems and multiple versions of those operating systems.

The proliferation of billions of proprietary devices has led to a growing set of problems surrounding software compatibility, security, and support, as well as hardware reliance for functionality. Virtualization technology, whether local or in the cloud, was initially envisioned as the solution, however increasing complexity, lack of compatibility with today’s hardware, unmet performance expectations and cost concerns are creating multiple barriers to adoption for businesses of all sizes.

In addition, with all these new “data creators” now online, we are seeing an incredible data explosion. With data production expected to grow 44 fold between 2009 and 2020, there is enormous pressure on enterprises that are responsible for the storage, protection and management of this unstructured data. Consequently there is a significant market opportunity for us to assist organizations to address these problems and we find ourselves well positioned to do so.

We believe the investments we have made in our proprietary containerization approach to virtualization, distributed hyper-convergence, and scale out data management architectures, are disruptive forces that can challenge the status-quo in IT. Going forward, the tenets of our growth strategy encompass leveraging our 30 years of innovation to deliver leading edge technologies, accelerating adoption of those technologies through our world class distribution and partner ecosystem, and expanding our strategic partnerships to deliver new business models and services.

Evidence of this strategy can be found in some of our recent successes in helping organizations deal with real world problems. I would like to highlight just a few of these since completing the Overland acquisition on December 1, 2014:

  • Earlier this month, we announced that our flagship container platform that virtualizes applications, Glassware 2.0®, was able to solve platform compatibility issues for New Caney ISD, an independent school district in Texas. New Caney is one of the largest deployments of Chromebooks in education, with over 10,000 devices used by students. They were looking for a way to deliver certain Windows-based applications, including graphically intense applications used in their labs, to student Chromebooks – quickly and affordably. Through our unique approach, we were able to deliver where others could not, and future-proofed their device investment at the same time.
  • In healthcare, through our partnership with Novarad, we are delivering Glassware 2.0 on purpose-built appliances for virtualization of medical imaging software, and providing our V3 hyper-converged platform for virtual desktop deployments. This approach allows customers to deploy a 100% virtual workspace versus having to manage both virtual and physical desktops — a relatively common occurrence due to limitations in virtualizing certain types of applications through conventional technologies. Both Glassware and V3 platforms come with simple user interfaces which reduce time spent on managing infrastructure, freeing up more time for delivering critical IT functions to users.
  • In the Managed Service Provider (MSP) segment we are working with Ericsson and are at various stages of proof of concept (POC) and pilot programs with some of North America’s leading telecommunication companies. In conjunction with our partners, we are offering a unique distributed hyper-converged infrastructure and associated management software that enable flexible virtual desktop deployments with unparalleled performance.
  • In the financial services segment, we are helping customers redefine their end-to-end data management infrastructure and provide them multi-tier protection for their distributed enterprise environment. With the combination of our scale-up and scale-out storage portfolio, and with our RDX QuikStor removable storage solutions, customers are enjoying online and off-line data protection coupled with enhanced data mobility that is uniquely possible with Sphere 3D’s versatile data protection offerings.

With over 1.3 billion people around the world utilizing Windows operating systems, we are seeing increased interest in our Glassware containerization technology for Windows applications, and are being asked to assist organizations with everything from converting legacy 16, 32 and 64 bit applications to providing virtual applications for customers that don’t require a complete virtual desktop for their users. We recently announced that we have become a Microsoft® OEM Embedded partner which allows us to better serve our customers and provide them with a simplified Windows licensing schema.

In addition to our customer successes, we are pleased to see a renewed vigor from the Overland partner ecosystem as we begin to introduce new disruptive technologies. We recently announced an expanded relationship with Promark, an Ingram Micro company and one of the world’s largest distributors of IT. Our worldwide network of field representatives are training and supporting additional partners as we ramp up availability of our new technologies. Through this renewed commitment from our channel partners, we have been adding additional listings of Sphere 3D technologies to GSA (US General Services Administration) contracts and will continue to do so throughout the year. At the same time, we are continuing to see stronger commitment and focus from our worldwide OEM partners who continue to thrive and see their businesses grow considerably through the differentiated value proposition of our offerings in their respective markets.

It is truly exciting to see enterprise experience and start-up innovation come together under the same umbrella to usher in a new era of opportunity — opportunity for our 400+ employees, our thousands of partners in over 90 countries, our growing installed base of over 1 million units, and for our shareholders.

We have come a long way since our inception just a few short years ago and have had a very transformative 2014. We have made the transition from research and development to commercial operations, we have bolstered our execution capabilities, and we have expanded our intellectual property portfolio, both organically and through acquisition.

Finally, let me say that it is gratifying to see how our products generate excitement and create new possibilities. Our organization is driven to succeed and although there is still hard work that lies ahead, we are confident 2015 will unlock additional opportunities that will serve to benefit our shareholders, partners and customers.

Thank you for your continued support.

Sincerely,

Eric L. Kelly
CEO and Chairman
Sphere 3D Corporation

About Sphere 3D
Sphere 3D Corporation (NASDAQ: ANY) is a virtualization technology and data management solutions provider with a portfolio of workload-optimized, purpose-built solutions that address the complete IT workspace delivery and management including the data lifecycle continuum from active data to data at rest. Dedicated to continue to lead through innovation, Sphere 3D enables the integration of virtual applications, virtual desktops, and storage into workflow, and allows organizations to deploy a combination of public, private or hybrid cloud strategies. Sphere 3D’s Glassware 2.0® platform delivers virtualization of some of the most demanding applications in the marketplace today, making it easy to move applications from a physical PC or workstation to a virtual environment. Sphere 3D’s V3 hyper-converged infrastructure solutions include one of the industry’s first purpose-built appliances for virtual workspace workloads and the Desktop Cloud Orchestrator™ management software for VDI. Overland Storage and Tandberg Data, wholly-owned subsidiaries of Sphere 3D, provide an integrated range of technologies and services for primary, nearline, offline, and archival data storage that make it easy and cost-effective to manage different tiers of information over the data lifecycle. For more information, visit www.sphere3d.com.

Safe Harbor Statement
This press release contains forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties including, without limitation, any failure of Sphere 3D to secure additional capital to fund operations; changes in the course of Sphere 3D’s business or the business of its wholly-owned subsidiaries, including, without limitation, Overland Storage and Tandberg Data; the rate of customer adoption of our products and technologies; the ability of our newly announced partnerships and alliances to increase our revenue; any increase in Sphere 3D’s cash needs or in expected expenses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in Sphere 3D’s periodic reports contained in our Annual Information Form and other filings with Canadian securities regulators (www.sedar.com) and in prior periodic reports filed with the United States Securities and Exchange Commission (www.sec.gov, and risks detailed in the Form F-4/A relating to Sphere 3D’s merger with Overland Storage filed with the SEC. Sphere 3D undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:
Pattie Adams
Director, Global Corporate Communications
+1 408/283-4779
pattie.adams@sphere3d.com

Investor Contact:
MKR Group Inc.
Todd Kehrli or Jim Byers
+1 323/468-2300
any@mkr-group.com

Tuesday, February 17th, 2015 Uncategorized Comments Off on (ANY) Provides Business Update in Open Letter to Shareholders

(APDNW) Launches DNA Mark Identification Technology Platform — DNA Beacon(TM)

Encrypted Fluorescence Is Covert, Mobile and Adaptable Across Many Industries

STONY BROOK, NY–(February 17, 2015) – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, is launching a new technology, based on the use of a panel of novel, fluorescent, encrypted security elements, the patent-pending “DNA Beacon” technology, that is designed to integrate seamlessly with our SigNature® DNA platform.

The Beacon technology is designed to identify APDN DNA-marked products, by encrypted fluorescence, throughout an entire supply chain or through high-value asset chain-of-custody. By combining our flagship SigNature DNA mark with the new Beacon technology, APDN’s new combined technology platform can now accelerate the fight against counterfeiting, diversion and theft. Once a product is marked, identification in the field is easily conducted with the use of a simple Beacon activator (which chemically decrypts the Beacon) and a UV light, to be followed by forensic-grade DNA authentication, when required.

An indication of the unique robustness of the Beacon technology is its ability to survive flame temperatures in excess of 1000°C. Thus, it is well suited to prevent crimes such as copper theft where criminals sometimes burn the wire sheathing to expose bare copper for sale.

Many industries can take advantage of this new integrated [SigNature DNA + Beacon] technology platform: to protect consumer packaged goods, luxury brands, government commodities, copper, plastics, the printing and packaging of documents and labels for field inspection, and the protection of cash and valuables in the home or in transit. With this new technology pair, companies can realize higher confidence in field-level screening to combat counterfeiting, diversion and theft by integrating Beacon and SigNature DNA together as a combination taggant into their product lines.

The technology has already been endorsed and incorporated in labeling solutions provided by CCL Label, a world leader in security labeling and packaging. Additional feasibility trials have taken place with customers in the electronics, athletic wear, pharmaceuticals, plastics and book-publishing businesses.

This new technology platform complements APDN’s current product, solution and service portfolio, including the recently announced Multi-Modal reader prototype. These interlocking platforms offer the marketplace an array of DNA-based security solutions, which enable users to DNA-mark, identify and authenticate a product or asset as it moves through a secure supply chain or between people or facilities.

“Beacon is another breakthrough technology allowing us to address the demands of our customers to conduct covert in-field inspections, protecting their products and assets,” said Dr. James Hayward, President and CEO, Applied DNA Sciences.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences’ common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statement
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, and our subsequent quarterly report on Form 10-Q, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact:
Debbie Bailey
631-240-8817
Email contact

media contact:
Enrique Briz
Dian Griesel Int’l.
212-825-3210
Email contact

program contact:
Judy Murrah
CIO
631-240-8819
Email contact

Tuesday, February 17th, 2015 Uncategorized Comments Off on (APDNW) Launches DNA Mark Identification Technology Platform — DNA Beacon(TM)

(EGRX) & (TEVA) License to Commercialize Bendamustine Rapid Infusion Product

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) today announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride (HCl) rapid infusion product for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva.

Eagle has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Eagle has requested Priority Review of the NDA; this product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL, and therefore may be eligible for seven years of exclusivity upon approval. The NDA is supported by data from Eagle’s recently-completed clinical trials demonstrating that the rapid infusion bendamustine HCl product can be administered in ten minutes in a low-volume, 50 mL admixture.

“Since 2008, Teva’s bendamustine HCl product, TREANDA®, has played a valuable role in the treatment of patients with CLL or indolent B-cell NHL that has progressed,” stated Paul Rittman, Vice President and General Manager, Teva Oncology. “With a substantially shorter infusion time, Eagle’s rapid infusion bendamustine HCl represents an important and improved benefit to both patients and healthcare providers. By adding this product to Teva’s Oncology portfolio, we are furthering our commitment to enhancing treatment options for patients affected by cancer and executing on a business development strategy to pursue opportunities in therapeutic areas where we can apply our expertise, commercial infrastructure and experience.”

“We are very pleased to partner with Teva for the commercialization of our rapid infusion bendamustine product,” said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals. “Given their strong presence and unsurpassed knowledge of this market, we believe there is no better company than Teva to optimize the market potential of this product.”

As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30 million and is eligible to receive up to $90 million in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval.

The companies will also settle the pending patent infringement action between them in the United States District Court for the District of Delaware involving Teva’s U.S. Patent No. 8,791,270.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.

About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA’s 505(b)(2) regulatory pathway. Eagle currently markets RYANODEX® (dantrolene sodium) in the U.S. for the treatment of malignant hyperthermia. Additional information is available on the company’s website at www.eagleus.com.

RYANODEX® is a registered trademark of Eagle Pharmaceuticals, Inc.

TREANDA® (bendamustine HCI) Injection Indications
TREANDA® is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

TREANDA® is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

  • Allergic Reactions: Patients with a known allergic response to bendamustine should not take TREANDA®.
  • Serious Side Effects: TREANDA® may cause serious side effects, including low blood cell counts, infections, unexpected responses to TREANDA® when placed in your blood, sudden and severe allergic responses, kidney failure due to fast breakdown of cancer cells, other cancers, and leaking of TREANDA® out of your vein and into your surrounding skin. Some of these side effects, such as low blood counts, infections, and severe allergic skin responses (when TREANDA® was given with allopurinol and other medications known to cause severe allergic skin responses), have caused death. Tell your doctor right away if you have any of these side effects.
  • Changes in Therapy: Some serious side effects may require changes in therapy, such as lowering the amount of TREANDA® given, stopping the use of TREANDA® or waiting longer than expected between doses of TREANDA®.
  • Pregnancy: Women should avoid becoming pregnant while using TREANDA® because it may cause fetal harm if you take TREANDA® while pregnant.
  • Most Common Side Effects: The most common non-blood-related side effects associated with TREANDA® (occurring in ≥15% of patients) are nausea, fatigue, vomiting, diarrhea, fever, constipation, loss of appetite, cough, headache, weight loss, difficulty breathing, rash, and mouth irritation. The most common blood-related side effects associated with TREANDA® (frequency ≥15%) are decreased number of three different types of white blood cells (infection-fighting cells), low red blood cells (oxygen-carrying cells), and low platelets (blood-clotting cells).

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for TREANDA® Full Prescribing Information.

TREANDA® is a registered trademark of Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.

Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, which are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our innovative products, especially Copaxone® (including competition from orally-administered alternatives, as well as from potential purported generic equivalents) and our ability to migrate users to our new 40 mg/mL version; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from the research and development efforts invested in our pipeline of specialty and other products; our ability to reduce operating expenses to the extent and during the timeframe intended by our cost reduction program; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Eagle’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events including, but not limited to: acceptance for filing by the FDA of the NDA for the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen; the decision of the FDA on Eagle’s request for Priority Review for this NDA; success in gaining timely FDA approval of the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen; the timing and level of success of a future launch of the rapid infusion bendamustine product by Teva; the success of Eagle’s commercial arrangement with Teva and the parties’ ability to work effectively together; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the year ended September 30, 2014, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to: whether the FDA will accept Eagle’s NDA for the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen; whether the FDA will grant Priority Review of the NDA or whether the FDA will ultimately approve the NDA, at all; whether Teva will be successful at commercializing the rapid infusion bendamustine product; whether Eagle and Teva will successfully perform each of their respective obligations under the exclusive license agreement; and other risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
or
United States
Ran Meir, 215-591-3033
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Iris Beck Codner, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974
or
United States
Nancy Leone, 215-284-0213
or
Eagle
In-Site Communications
Lisa Wilson, 212-452-2793
or
Amy Raskopf, 917-673-5775

Tuesday, February 17th, 2015 Uncategorized Comments Off on (EGRX) & (TEVA) License to Commercialize Bendamustine Rapid Infusion Product

(ROSG) Announces Key Patent Allowances in U.S. and Europe

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming the use of miR-34a for the treatment of p53-associated cancers. In addition, the Company announced its first allowance from the European Patent Office for a patent claiming the specific composition for miR-451, a miR relating to the Company’s Cancer of Unknown Primary (CUP) testing franchise.

The allowed claims for the U.S. Patent Application No. 14/280,822 entitled “Composition and Methods For Modulating Cell Proliferation and Cell Death” cover a core element of Rosetta Genomics’ microRNA technology in the development of cancer therapeutics relating to cancers associated with the p53 gene. This patent is broader than the previous patent issued last year in that it covers the treatment of any p-53 associated cancer using miR-34a or its variants, delivered by any kind of formulation.

The patent is jointly owned with Yeda Research and Development, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.

The p53 protein is a sequence-specific transcription factor that functions as a major tumor suppressor in mammals. Inactivation of the p53 tumor-suppressor function is one of the most frequent genetic alterations in human cancer, and more than half of all human tumors carry p53 gene mutations within their cells. In addition, mutations in p53 have been correlated with clinical aggressiveness.

“p53 plays an important role in many cancers. Consequently, a therapeutic based on mimicking miR-34a that can potentially overcome some of the negative effects of mutations in this important tumor suppressor holds significant promise,” commented E. Robert Wassman, M.D., Rosetta Genomics’ Chief Medical Officer.

The allowed claims for European Patent Application Number 05766834.5 entitled, “MicroRNAs and uses thereof” cover miR-451 and its complement, as well as a probe comprising the claimed miR. Therapeutic and diagnostic uses of the miR and/or the probe are also covered in the allowed claims.

“We continue to fortify our leading intellectual property position in microRNA technology as well as microRNAs themselves and these new patents expand, strengthen and complement our growing portfolio of over 40 patents worldwide,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Patents such as this recent one in the U.S. are important as they not only protect key elements of our microRNA technology to develop a variety of oncology treatments that are associated with the p53 tumor suppressor, but they also offer multiple opportunities for monetization through potential drug development partnerships or other licensing arrangements. Separately, this recent European composition of matter patent strengthens and expands the patent protection for our CUP testing franchise and further establishes our global leadership position in microRNA technology.”

“Importantly, both of these patents support our broader oncology strategy to develop and commercialize microRNA-based diagnostics, therapeutics and biomarkers on a global basis in order to enhance clinicians’ ability to identify and treat cancers,” concluded Mr. Berlin.

About Rosetta Cancer Testing Services

Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta’s assays are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test™, 60,000 from the Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta’s cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, Rosetta’s Cancer of Origin Test™, Rosetta’s development or commercialization of molecular diagnostics or therapeutics, the market acceptance of Rosetta’s cancer testing services, particularly the Rosetta Cancer Origin Test™, Rosetta’s development of personalized medicine products and services, the reproducibility, robustness and accuracy of Rosetta’s microRNA technology and its ability to help enable personalized medicine and optimize treatment, the expansion of payor coverage of Rosetta’s testing services, and the amount of people covered for the Rosetta testing services, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company:
Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
investors@rosettagenomics.com
or
Investors:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Tuesday, February 17th, 2015 Uncategorized Comments Off on (ROSG) Announces Key Patent Allowances in U.S. and Europe

(CAPN) Announces First U.S. Commercial Sales of CoSense(R)

REDWOOD CITY, Calif., Feb. 17, 2015  — Capnia, Inc. (Nasdaq:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced the first U.S. commercial sales of the Company’s CoSense End-Tidal Carbon Monoxide (ETCO) Monitors and single-use sampling sets to leading academic, research and healthcare institutions. CoSense is a portable, non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. The measurement of carbon monoxide is the gold standard for measuring hemolysis, a condition that, if left untreated, may lead to elevated levels of bilirubin in the blood and a range of neurodevelopmental disorders in newborns.

“We have made significant progress to date with the U.S. commercialization of CoSense, the only available device for accurately and non-invasively measuring ETCO in newborns,” said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. “These first customers, which include a prestigious academic institution and an internationally recognized nonprofit hospital system, underscore the potentially significant and diversified markets for this unique device. As we continue to execute our staged commercial rollout of CoSense, we remain focused on our goal of making this important product widely available.”

Of the 140 million babies born worldwide and 9.2 million babies born annually in the in the U.S. and European Union, more than 60% will present with jaundice at some point in the first five days of life. Jaundice is caused by the pigment bilirubin and may be a sign of excessive breakdown of red blood cells, or hemolysis. In infants, bilirubin is toxic to the brain and central nervous system. Exposure to high levels of bilirubin in newborns may lead to permanent neurological damage. These neurological abnormalities range from subtle ones such as learning disabilities and impaired hearing to severe life threatening outcomes such as acute bilirubin encephalopathy, or a chronic disabling disease called kernicterus.

The American Academy of Pediatrics guidelines state that ETCO monitoring is the only clinical test that provides a direct measurement of the rate of bilirubin production, and therefore hemolysis. The guidelines recommend ETCO measurement be performed to assess the presence of hemolysis in neonates in several clinical circumstances. CoSense is the only available device to accurately measure the ETCO levels in neonates and therefore the only device that enables physicians to practice in accordance with the AAP guidelines when evaluating jaundiced neonates for potential treatment.

About Hemolysis

Hemolysis refers to the rapid or excessive breakdown of red blood cells, a process which produces bilirubin at an accelerated rate, resulting in jaundice. Approximately 60% of healthy infants and 80% of premature infants have jaundice during the neonatal period. Many causes of jaundice do not represent a significant health threat, yet it is the most common cause of hospital readmission for newborns. Severe jaundice in the presence of hemolysis is a predictor of adverse neurodevelopmental outcomes such as low IQ, auditory abnormalities and kernicterus. Rapid diagnosis and treatment of this condition may be necessary for infants to avoid life-long neurological impairment or other disability.

About Capnia

Capnia, Inc. develops and commercializes novel products based on its proprietary technologies for precision metering of gas flow. Capnia’s lead product is CoSense, which aids in the detection of hemolysis, a dangerous condition in which red blood cells degrade rapidly. CoSense, based on the Sensalyze™ Technology platform, is a portable non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. CoSense has 5010(k) clearance from the FDA and also received CE mark approval for sale in the E.U. Capnia’s proprietary therapeutic technology uses nasal, non-inhaled CO2 to treat symptoms of allergies, as well as the trigeminally-mediated pain conditions such as cluster headache, trigeminal neuralgia and migraine.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned product development and clinical trials and that measuring ETCO may be an effective way to identify pathological hemolytic conditions.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in Capnia’s Form S-1 filed with the Securities and Exchange Commission on November 14, 2014, including under the caption titled “Risk Factors.” Capnia expressly disclaims any intent or obligation to update these forward looking statements, except as required by law.

CONTACT: Capnia Contact:
         David O'Toole
         Chief Financial Officer
         Capnia, Inc.
         (650) 353-5146
         dotoole@capnia.com

         Investor Relations Contact:
         Michelle Carroll/Susie Kim
         Argot Partners
         (212) 600-1902
         michelle@argotpartners.com
         susie@argotpartners.com
Tuesday, February 17th, 2015 Uncategorized Comments Off on (CAPN) Announces First U.S. Commercial Sales of CoSense(R)

(VSTA) NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Similar to Ketamine, AV-101 Has a Fundamentally Novel Mechanism of Action Compared to All Approved Antidepressants

SOUTH SAN FRANCISCO, CA–(Feb 17, 2015) – VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system (CNS), has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Under the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored Phase 2 clinical study of AV-101, VistaGen’s orally-active NMDA receptor modulator, in subjects with Major Depressive Disorder (MDD). MDD is a widespread and debilitating mental disorder affecting millions worldwide, including nearly 7% of U.S. adults.

Dr. Carlos Zarate, Chief of the Section on the Neurobiology and Treatment of Mood Disorders and Chief of the Experimental Therapeutics and Pathophysiology Branch at the NIMH, will be the Principal Investigator of the NIH-funded study, which will be a randomized, double-blind, placebo-controlled, crossover Phase 2 clinical trial designed to evaluate the efficacy and safety of a single oral dose of AV-101 administered once per day for 14 days to approximately 25 subjects with MDD. The primary efficacy measure will be the Hamilton Depression Rating Scale (HDRS), a standard scale for measuring depression severity. VistaGen and the NIH anticipate completing the study in 2015.

“We are excited by the strong preclinical efficacy data supporting the ketamine-like antidepressant effects of AV-101, as well as the rapid and efficient oral-delivery and clinical safety range demonstrated by our successful Phase 1 clinical studies,” said H. Ralph Snodgrass, VistaGen’s President and CSO. “Dr. Zarate and his team have deep experience with ketamine and other NMDA receptor antagonists. We look forward to collaborating closely with them to complete this important AV-101 Phase 2 study in MDD by year end.”

About MDD and Current Antidepressants
Most people will experience depressed mood at some point during their lifetime, but MDD is different. MDD is the chronic, pervasive feeling of utter unhappiness and suffering, which impairs daily functioning. Symptoms of MDD include diminished pleasure in activities, weight changes, insomnia or hypersomnia, psychomotor agitation, fatigue, feelings of worthlessness and guilt, poor concentration and suicidal thoughts and behaviors. Suicide is estimated to be the cause of death in up to 15% of individuals with MDD.

Current medications available in the multi-billion dollar global antidepressant market, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), have limited effectiveness, and because of their mechanism of action, SSRIs and SNRIs must be taken for several weeks before patients experience any significant therapeutic benefit. Over 60% of depression sufferers do not benefit from first round treatments, and the likelihood of achieving remission of depressive symptoms declines with each successive treatment attempt. Although approximately two out of three patients may find an antidepressant drug or drug combination that induces remission of their depressive symptoms after as many as four treatment attempts during the course of up to more than a year, this trial and error process and the systemic effects of the various antidepressant medications involved increases the risks of patient tolerability issues and serious side effects, including suicidal thoughts and behaviors.

About Ketamine for MDD
In randomized, placebo-controlled, double-blind clinical trials conducted by Dr. Zarate and others at the NIMH, ketamine (an NMDA receptor antagonist which acts as an NMDA channel blocker) produced robust and rapid, within hours, antidepressant effects in MDD patients who had not responded to approved antidepressants. Although the potential for widespread therapeutic use of ketamine is limited by its potential for abuse, dissociative and psychosis-like side effects, and practical challenges associated with its required intravenous administration in a medical center, the discovery of ketamine’s rapid onset antidepressant effects revolutionized thinking about the MDD treatment paradigm and mechanism of action of antidepressant medicines. The discovery also increased interest in the development of a new generation of antidepressants with a mechanism of action similar to ketamine’s, including a more rapid therapeutic benefit compared to existing agents.

About AV-101 for MDD
AV-101 is a unique, orally-active, prodrug candidate that produces, in the brain, 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and selective antagonists of the glycine-binding site of the NMDA receptor, resulting in the down-regulation of NMDA signaling. Growing evidence suggests that the glutamatergic system is central to the neurobiology and treatment of MDD and other mood disorders.

AV-101’s fundamentally novel mechanism of action places it among a new generation of glutamatergic antidepressants with breakthrough potential to treat millions of MDD sufferers worldwide who are poorly served by SSRIs, SNRIs and other current depression therapies. Like ketamine, AV-101 modulates (down-regulates) NMDA receptor channel activity. However, unlike ketamine’s antagonistic activity, which results from its blocking the NMDA receptor channel, AV-101’s antagonistic activity results from its selective binding to, and blocking of, the functionally-required glycine-binding co-agonist site of the NMDA receptor. Targeting the glycine-binding co-agonist site of the NMDA receptor may bypass potential adverse effects that occur with ketamine without affecting the robust efficacy observed in previous clinical studies. This may then result in the “glutamate surge” that has been associated with the rapid-acting antidepressant effects of ketamine.

The NIH previously awarded VistaGen $8.8 million to advance its preclinical and Phase 1 clinical development of AV-101. In two randomized, double-blind, placebo-controlled Phase 1 safety studies, AV-101 was well tolerated and not associated with any severe adverse events. There were no signs of sedation, hallucinations or schizophrenia-like side effects often associated with ketamine and traditional NMDA receptor channel blockers.

About the U.S. National Institute of Mental Health
The U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH), is the largest scientific organization in the world dedicated to mental health research. NIMH is one of 27 Institutes and Centers of the NIH, the world’s leading biomedical research organization. The mission of NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure. For more information, visit www.nimh.nih.gov.

About VistaGen Therapeutics
VistaGen is a clinical-stage biopharmaceutical company developing innovative medicine for depression and diseases and conditions involving the central nervous system (CNS). VistaGen’s AV-101 is a new generation orally-available NMDA receptor glycine B-site antagonist entering Phase 2 clinical development for Major Depressive Disorder. Based on preclinical studies, AV-101 may also have potential as a treatment for other CNS-related conditions, including chronic neuropathic pain and epilepsy, as well as neurodegenerative diseases such as Parkinson’s disease and Huntington’s disease. VistaGen is also leveraging its proprietary pluripotent stem cell technology and clinically-predictive bioassay systems, CardioSafe 3D™ and LiverSafe 3D™, for drug rescue applications focused on producing proprietary new chemical entities (NCEs) that are novel, safer versions of drug candidates previously optimized and tested for efficacy by pharmaceutical companies and others but terminated before FDA approval due to heart or liver toxicity.

Visit VistaGen at http://www.VistaGen.com
Follow VistaGen on Twitter at http://www.twitter.com/VistaGen
Connect to VistaGen’s Facebook page at http://www.facebook.com/VistaGen

Cautionary Statement Regarding Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the VistaGen’s and the NIH’s successful completion of the NIH-sponsored Phase 2 clinical study of AV-101 in MDD under the CRADA, its stem cell technology-based drug rescue activities, protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the foregoing activities. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For more information:
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-577-3613
Investor.Relations@VistaGen.com

Mission Investor Relations
IR Communications
Atlanta, Georgia
www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Tuesday, February 17th, 2015 Uncategorized Comments Off on (VSTA) NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

(BBEP) Conference Call & Webcast to Discuss Q4 and Year-End 2014 Results

Breitburn Energy Partners LP (NASDAQ:BBEP) will hold a conference call on Tuesday, March 3, 2015, at 10 am (PST) following the release of its fourth quarter and year-end 2014 financial results.

The conference call may be accessed by calling 888-539-3612 (international callers dial 719-325-2244) or via webcast at http://ir.breitburn.com/. An archived edition of the conference call will also be available through March 10, 2015, by calling 877-870-5176 (international callers dial 858-384-5517) and entering replay PIN 8598867 or by visiting http://ir.breitburn.com/.

About Breitburn Energy Partners LP

Breitburn Energy Partners LP is a publicly-traded, independent oil and gas master limited partnership focused on the acquisition, development, and production of oil and gas properties throughout the United States. Breitburn’s producing and non-producing crude oil and natural gas reserves are located in the following seven producing areas: the Permian Basin, Michigan/Indiana/Kentucky, Ark-La-Tex, the Mid-continent, the Rockies, Florida, and California. See www.breitburn.com for more information.

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Breitburn expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by Breitburn based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond Breitburn’s control and are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. The reader should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, Breitburn undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Unpredictable or unknown factors not discussed herein also could have material adverse effects on forward-looking statements. See “Risk Factors” in Breitburn’s Annual Report filed on Form 10-K and other public filings and press releases.

BBEP-IR

Breitburn Energy Partners LP
Antonio D’Amico
Vice President, Investor Relations & Government Affairs
or
Jessica Tang
Investor Relations, Manager
(213) 225-0390

Friday, February 13th, 2015 Uncategorized Comments Off on (BBEP) Conference Call & Webcast to Discuss Q4 and Year-End 2014 Results

(LBTYB) & Virgin Media Announce Huge Investment in UK’s Internet Infrastructure

Virgin Media, the UK’s ultrafast internet provider, is embarking on “Project Lightning” the single largest investment in broadband digital infrastructure in the country for more than a decade; creating thousands of new jobs in what will be a multi-billion pound boost to the national economy.

With the support of parent company Liberty Global plc (“Liberty Global”) (Nasdaq: LBTYA, LBTYB, LBTYK), Virgin Media will extend its unrivalled fibre-rich network to approximately four million additional premises over the next five years. This will increase the number of homes and businesses to which Virgin Media can offer services by almost a third; from around half of the country today to nearly 17 million premises by 2020.

£3 billion for homes and businesses; £8 billion of value to the UK economy and consumers

The UK is the world’s most internet-based major economy (Source: Ofcom). Broadband infrastructure, and the services offered over it, will be increasingly central to the country’s growth over the coming decades.

The £3 billion of additional private investment announced today is essential for individuals and businesses to thrive in the global digital economy. This substantial investment will be financed mainly through incremental borrowings. Analysis undertaken by leading economic consultancy Oxera has found that this investment can be expected to stimulate a combined £8 billion of economic activity and consumer benefit.

Prime Minister David Cameron said: “I welcome this substantial investment from Virgin Media which is a vote of confidence in our long-term economic plan to support business and create jobs by building a superfast nation backed by world-class infrastructure. These 6,000 new jobs and apprenticeships will mean financial security and economic peace of mind for thousands more hardworking families across the country. Together with this Government’s rollout of superfast broadband which has now reached more than two million UK homes and businesses, this additional private investment will create more opportunities for people and businesses, further boosting our digital economy and helping secure a brighter future for Britain.”

Tom Mockridge, Virgin Media Chief Executive Officer, said: “Millions of homes and businesses will soon be able to benefit for the first time from broadband speeds at least twice as fast as those available from the other major providers. Consumers and business owners who want to make the switch to better broadband speeds now have an alternative; you can call on Virgin Media to ‘Cable My Street’.”

Mike Fries, Liberty Global Chief Executive Officer, said: “Our next-generation fibre-rich networks reach 50 million households across Europe, enabling our customers to discover and experience the endless possibilities of the digital world. After a record operating performance, Project Lightning is a significant investment that demonstrates the confidence we have in Virgin Media and the UK as a place to do business.”

Households connecting to Virgin Media for the first time will benefit from broadband speeds of 152Mb, at least twice as fast as the fastest speeds available from BT, TalkTalk and Sky. Virgin Media also offers the UK’s most advanced interactive television service, bringing together broadcast TV, thousands of hours of on demand programming and the best of the web in a single set-top box.

Home workers and small and medium-sized companies will also receive a boost from better connectivity in areas where Virgin Media Business will become available for the first time.

When it comes to making the most of increasingly connected lives, speed and capacity matters. The number of internet-enabled devices has grown significantly in the past decade, as homes and businesses are increasingly connected to multiple devices simultaneously. Sixty per cent of Virgin Media customers now have at least three devices connected to their home broadband, up from 37 per cent a year ago. Data usage on the Virgin Media network is currently growing at a rate of around 60 per cent every year which, if this trend continues, will be 10,000 per cent higher in ten years.

6,000 UK jobs created; award-winning apprenticeship scheme expanded

This network expansion programme is expected to create 6,000 new jobs in the UK at Virgin Media and across its construction partners. Roles will be created across the country, including jobs to support engineering and sales efforts.

It will increase the number of apprenticeships created by Virgin Media to 1,000 over the next five years. Almost 1,000 young people have already gained recognised skills and experience in this award-winning scheme while earning, since it began in 2008. Further information about working for Virgin Media is available at virginmedia.com/careers.

Virgin Media calls on consumers and businesses to register their interest

Network expansion will be prioritised according to demand from households and companies, with a focus on areas closest to Virgin Media’s existing network.

Virgin Media is urging communities who want better connectivity to register their interest at virginmedia.com/cablemystreet.

Businesses can register at virginmediabusiness.co.uk/cablemybusiness.

Tom Mockridge, Virgin Media Chief Executive Officer, added: “In virtually all of the areas we have identified for expansion, BT is the only option available right now. Its ageing copper telephony wires are not capable of the ultrafast connectivity that Virgin Media delivers. Soon we will offer unbeatable services to even more homes and businesses across the country.”

Long term investment in speed leadership; Virgin Media – always faster

Today’s announcement of “Project Lightning” marks a five-year transformation of Virgin Media to extend its existing position as ‘always faster’ to more areas as the better alternative to the incumbent BT’s network.

Liberty Global is a global leader in innovation and new technologies and is preparing trials of DOCSIS 3.1 technology across Europe later this year. This technology could extend Liberty Global’s speed leadership to up to 10Gb when it is fully deployed in the future.

Virgin Media Business – transforming the prospects of enterprise

Virgin Media Business offers telecoms services specifically designed to help small and medium companies grow. These are tailored to cover those starting out, as well as growing, emerging and maturing businesses, helping to reduce complexity and make it easier for firms to seize business opportunities every day.

A new proposition specifically designed for the start-up hotspot of east London means Virgin Media Business is installing managed internet access to buildings with shared occupancy. Once the fibre is installed, each of the small businesses in a building will get their own dedicated connection. There are plans to extend this multi-tenant capability across other parts of the UK.

Notes to Editors

Ofcom: Importance of the UK’s internet economy revealed, December 2014 http://media.ofcom.org.uk/news/2014/icmr-2014/

Virgin Media is already in the process of expanding its network to 110,000 homes across east London, Glasgow, Sunderland and Teesside.

About Virgin Media

Virgin Media is the first provider of all four broadband, TV, mobile phone and home phone services in the UK. The company’s cable network – the result of multi-billion pound private investment – delivers ultrafast broadband to over half of all UK homes, with speeds of up to 152Mb, as well as market leading connectivity to thousands of public and private sector organisations across the country.

Virgin Media has developed the most advanced interactive television service, bringing together broadcast TV, thousands of hours of on demand programming and the best of the web in a single set-top box powered by TiVo. The company was the first to offer HD TV and 3D on demand to millions of British households.

The world’s first virtual mobile network was launched by Virgin Media and it is also one of the largest fixed-line home phone providers in the country.

Virgin Media is a part of Liberty Global plc, the world’s largest international cable company. Together Virgin Media and Liberty Global serve 27 million customers across 14 countries, helping connect people to the digital world and enabling them to discover and experience its endless possibilities.

Disclaimer

This press release contains forward-looking statements, including statements regarding Virgin Media’s investment plans and programme to extend its internet infrastructure, the amount of the investment, the timing and phasing of the investment and roll-out of broadband services, the number of homes and businesses to be reached as a result of the investment programme and the economic benefits and impacts of such investment, and other information and statements that are not historical fact. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. These risks and uncertainties include the continued use by subscribers and potential subscribers of our services and their willingness to upgrade to our more advanced offerings, our ability to meet challenges from competition, to manage rapid technological change or to maintain or increase rates, general economic factors, the continued growth in services for digital television at a reasonable cost, the effects of changes in laws or regulation, our ability to successfully acquire attractive programming for our digital video services and the costs associated with such programming, our ability to maintain certain accreditations, our ability to achieve expected operational efficiencies and economies of scale, our ability to generate expected revenue and operating cash flow, control property and equipment additions as measured by a percentage of revenue, the impact of our future financial performance, or market conditions generally, on the availability, terms and deployment of capital, fluctuations in currency exchange and interest rates, the ability of vendors and suppliers to timely deliver quality products, as well as other factors detailed from time to time in our most recent quarterly and annual report and Liberty Global’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date of this release. We expressly disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Friday, February 13th, 2015 Uncategorized Comments Off on (LBTYB) & Virgin Media Announce Huge Investment in UK’s Internet Infrastructure

(OCLR) Prices Offering of $55 Million of 6.00% Convertible Senior Notes Due 2020

SAN JOSE, Calif., Feb. 13, 2015  — Oclaro, Inc. (Nasdaq: OCLR), announced today the pricing of its offering of $55,000,000 aggregate principal amount of 6.00% Convertible Senior Notes due 2020 (the “Convertible Notes”). The Convertible Notes will be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), by the initial purchaser of the Convertible Notes. Oclaro has also granted the initial purchaser of the Convertible Notes a 30-day option to purchase up to an additional $10,000,000 aggregate principal amount of the Convertible Notes.

Oclaro intends to use the net proceeds of the offering for general corporate purposes, including working capital.

The Convertible Notes will mature on February 15, 2020 and will bear interest at a fixed rate of 6.00% per year, payable on February 15 and August 15 of each year, beginning August 15, 2015. The Convertible Notes will be general senior, unsecured obligations of Oclaro. The Convertible Notes will not be redeemable at Oclaro’s option prior to February 15, 2018. On or after February 15, 2018, the Convertible Notes will be redeemable at Oclaro’s option if the last reported sale price of Oclaro’s common stock for at least 20 trading days (which need not be consecutive trading days) in any 30 trading day period exceeds 130% of the conversion price for the Convertible Notes. The redemption price will equal 100% of the principal amount of the Convertible Notes being redeemed, plus accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date plus the sum of the present values of each of the remaining scheduled payments of interest that would have been made on the Convertible Notes being redeemed had such Convertible Notes remained outstanding from the redemption date to the maturity date. In addition, upon the occurrence of a fundamental change, holders of the Convertible Notes will have the right, at their option, to require Oclaro to repurchase their Convertible Notes in cash at a price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Convertible Notes will be convertible, at the option of the holders, into consideration consisting of, shares of Oclaro’s common stock (and cash in lieu of fractional shares) at any time prior to the close of business on the business day immediately preceding the maturity date. Prior to February 15, 2018, in the event that the last reported sale price of our common stock for 20 or more trading days (whether or not consecutive) in a period of 30 consecutive trading days ending within five trading days immediately prior to the date we receive a notice of conversion exceeds the conversion price in effect on each such trading day, we will, in addition to delivering shares upon conversion by the holder of the Convertible Notes, together with cash in lieu of fractional shares, make an interest make-whole payment. The initial conversion rate will be 512.8205 shares of Oclaro’s common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $1.95 per share of Oclaro’s common stock), representing an approximately 33.6% conversion premium to the $1.46 last reported sale price of Oclaro’s common stock on The NASDAQ Global Select Market on February 12, 2015. The conversion rate will be subject to adjustment upon the occurrence of certain events. In addition, Oclaro may be obligated to increase the conversion rate for any conversion that occurs in connection with a make-whole fundamental change and with Oclaro’s delivery of a notice of redemption for the Convertible Notes.

The offering is being made to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the Convertible Notes nor any shares of Oclaro’s common stock issuable upon conversion of the Convertible Notes have been or will be registered under the Securities Act or under any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

Safe Harbor Statement
This press release contains forward-looking statements for the purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995.  Such statements can be identified by the fact that they do not relate strictly to historical or current facts and may contain words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will,” “should,” “outlook,” “could,” “target,” “preliminary” and other words and terms of similar meaning in connection with any discussion of plans, objectives, goals, strategies and future operating or financial performance.  Undue reliance should not be placed on such forward-looking statements, which speak only as of the date they are made. Oclaro undertakes no obligation to update such forward-looking statements. Actual events and results may differ materially from those in the forward-looking statements and are subject to risks and uncertainties. Such risks and uncertainties include, but are not limited to, whether or not Oclaro will offer the Convertible Notes or consummate the offering, the anticipated terms of the Convertible Notes and the offering and the anticipated use of the proceeds of the offering.

Friday, February 13th, 2015 Uncategorized Comments Off on (OCLR) Prices Offering of $55 Million of 6.00% Convertible Senior Notes Due 2020

(APTO) Appoints Dr. Bradley Thompson to the Audit Committee

SAN DIEGO and TORONTO, Jan. 20, 2015  – Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that Dr. Bradley Thompson has been appointed to the Audit Committee, and that the NASDAQ Stock Market (“NASDAQ”) has notified the Company it has regained compliance with Listing Rule 5605 to maintain three independent members on the Audit Committee.

On December 15, 2014, Dr. Brian Underdown, a member of the Board of Directors and Audit Committee, resigned from the Aptose Board of Directors in conjunction with the appointment of Dr. Erich Platzer to the Board. This left the Audit Committee with only two independent members until Dr. Bradley Thompson was formally appointed to the committee. As previously reported on January 15, 2015 in the Company’s 6K filing with the Securities and Exchange Commission, on January 13, 2015 the Company received, as expected, a notification letter from NASDAQ stating that the Company no longer complied with NASDAQ’s audit committee requirements of maintaining committee membership by at least three independent directors as set forth in Listing Rule 5605 due to the resignation of Dr. Brian Underdown,  which was previously reported on December 15, 2014, in its Form 6-K filing with the Securities and Exchange Commission. The NASDAQ letter was issued in accordance with standard NASDAQ procedures.

Consistent with Listing Rule 5605(c)(4), NASDAQ provided the Company a cure period in order to regain compliance as follows:

  • until the earlier of the Company’s next annual shareholders’ meeting or December 15, 2015; or
  • if the next annual shareholders’ meeting is held before June 15, 2015, then the Company must evidence compliance no later than June 15, 2015.

 

On January 16, 2015 the Company appointed Dr. Bradley Thompson to the Audit Committee and was notified by NASDAQ today that the Company has regained compliance with Listing Rule 5605.

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies that address unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for its products. Aptose’s lead anticancer agent APTO-253 is under development for AML, MDS and other hematologic malignancies. For further information, please visit www.aptosebiosciences.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Friday, February 13th, 2015 Uncategorized Comments Off on (APTO) Appoints Dr. Bradley Thompson to the Audit Committee

(FEYE) Global Threat Intel Sharing Initiative at White House Summit on Cybersecurity

FireEye Provides Platform for Broader Sharing of Its Industry Leading Threat Intelligence Obtained Through Advanced Threat Detection Capabilities

MILPITAS, CA–(Feb 13, 2015) – FireEye, Inc. (NASDAQ: FEYE), the leader in stopping today’s advanced cyber attacks, today announced that it will launch its Global Threat Intelligence Sharing™ initiative as part of its commitment to helping companies leverage Adaptive Defense™ security architectures that better secure their organizations. The new initiative allows customers to quickly share anonymized FireEye threat intelligence with their partners, customers, and other trusted community members in order to develop a more robust community defense.

Powered by the FireEye Community Threat Intelligence™ (CTI™) platform, the initiative is designed to enable organizations to bi-directionally share threat intelligence with their community members in order to allow their business ecosystems to benefit from a unified cybersecurity strategy based on their unique threat landscape. CTI draws its intelligence from the FireEye Dynamic Threat Intelligence™ cloud, which delivers indicators of compromise developed from threats that have been identified by FireEye’s millions of virtual machines deployed on networks across the globe. Organizations will be enabled to deliver threat intelligence in near real-time to members of their specific community. CTI also allows members of a community to augment and correlate global attack data with intelligence specifically gathered in their business environment, giving context for both widespread attacks and highly-targeted threat actors against which they will likely have to defend.

“Today’s threat landscape demands far more than just broad attack data being exchanged without any context for those receiving it,” said David DeWalt, chairman of the board and CEO, FireEye. “Protecting each other from commodity attacks is important, but, by creating an initiative to protect an entire community, FireEye will automate defenses for broad attacks and power different levels of context and customization to protect the community from targeted attacks.”

FireEye Advanced Threat Intelligence Plus™ (ATI+™) can enable the initiative to provide an additional layer of context to all those within the customer’s community. Looking beyond the technical details of attacks, ATI+ layers in global context from news and analysis on advanced threat groups, strategic domestic and foreign policy initiatives, as well as profiles of targeted industries, including information about the types of data most valued by attackers.

More details on the FireEye Global Threat Intelligence Sharing initiative will be released in the coming months. In the interim, to learn more about the power of FireEye Threat Intelligence, please visit: https://www.fireeye.com/products/dynamic-threat-intelligence.html.

About FireEye, Inc.

FireEye has invented a purpose-built, virtual machine-based security platform that provides real-time threat protection to enterprises and governments worldwide against the next generation of cyber attacks. These highly sophisticated cyber attacks easily circumvent traditional signature-based defenses, such as next-generation firewalls, IPS, anti-virus, and gateways. The FireEye Threat Prevention Platform provides real-time, dynamic threat protection without the use of signatures to protect an organization across the primary threat vectors and across the different stages of an attack life cycle. The core of the FireEye platform is a virtual execution engine, complemented by dynamic threat intelligence, to identify and block cyber attacks in real time. FireEye has over 3,100 customers across 67 countries, including over 200 of the Fortune 500.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the capabilities, benefits and launch of the FireEye Global Threat Intelligence Sharing initiative. These forward-looking statements involve risks and uncertainties, as well as assumptions which, if they do not fully materialize or prove incorrect, could cause the results of this initiative to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause such results to differ materially include changes in the threat landscape; customer demand and adoption of FireEye’s solutions; real or perceived defects, errors or vulnerabilities in FireEye’s products or services; and general market, political, economic, and business conditions; as well as those risks and uncertainties included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in FireEye’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2014, which is available on the Investor Relations section of the company’s website at investors.FireEye.com and on the SEC website at www.sec.gov. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and FireEye does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made. Any future product, service, capability or benefit that may be referenced in this release is for information purposes only and is not a commitment to deliver any such product, service, capability or benefit. FireEye reserves the right to modify future product or services plans at any time.

© 2015 FireEye, Inc. All rights reserved. FireEye, Global Threat Intelligence Sharing, Adaptive Defense, Community Threat Intelligence, CTI, Advanced Threat Intelligence Plus and ATI+ is a registered trademark or trademark of FireEye, Inc. in the United States and other countries. All other brands, products, or service names are or may be trademarks or service marks of their respective owners.

Friday, February 13th, 2015 Uncategorized Comments Off on (FEYE) Global Threat Intel Sharing Initiative at White House Summit on Cybersecurity

(ENTL) Announces Release of XprESS(TM) Ultra Multi-Sinus Dilation System

PLYMOUTH, Minn., Feb. 13, 2015  — Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced the release of the XprESS™ Ultra Multi-Sinus Dilation System, the third device in the XprESS family of balloon sinus dilation systems.

XprESS Ultra provides the precision, versatility and control of the XprESS family of balloon sinus dilation systems while adding an even sleeker profile device to the XprESS family. The sleek profile and design of XprESS Ultra allows for smooth movement through tight nasal passages and easy endoscopic viewing of the treatment area while the malleable tip can be reshaped to meet the unique challenges of patients with extremely narrow sinus drainage pathways. “Entellus makes very intuitive products. The XprESS Ultra is a thinner tool that makes tight access easier,” said Dr. Rajiv Pandit, MD, Dallas ENT, Dallas Sinus Institute. With the addition of XprESS Ultra, the XprESS family now offers a choice of features to address patient needs and meet physician preferences.

The XprESS family of products are used by Ear, Nose and Throat, or ENT, physicians to treat patients with symptomatic inflammation of the nasal sinuses and open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. “The addition of XprESS Ultra to the XprESS family of devices highlights our ongoing commitment to making it even easier for ENT specialists to offer the benefits of balloon sinus dilation to patients suffering from sinusitis,” said Robert White, President and Chief Operating Officer, Entellus Medical, Inc.

About Chronic Sinusitis and Balloon Sinus Dilation:

Chronic sinusitis affects approximately 29 million American adults, making it one of the most common health problems in the U.S. It is more prevalent than heart disease and asthma, and has a negative impact on quality of life with chronic symptoms and effects including facial pain and pressure, headaches, fatigue, loss of smell, and sinus infections.

Surgical treatment of chronic sinusitis routinely involves cutting and removal of sinus mucosal tissue near the opening of a sinus. Use of sinus balloon technology preserves the natural sinus anatomy and enables effective treatment of sinusitis patients in the comfort and convenience of a physician’s office. In-office balloon sinus dilation is a proven, effective alternative treatment to endoscopic sinus surgery and provides patients lasting relief at a lower cost than traditional sinus surgery.

About Entellus Medical:

Entellus Medical is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical’s balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery, or FESS. Patients treated with Entellus Medical’s products in this trial in the ENT physician office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. Entellus Medical currently markets its products in the United States and Canada and sells its products through a direct sales force in the United States.

Forward-Looking Statements:

All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause the performance of the Entellus XprESS Ultra device or Entellus Medical’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the company’s significant operating expenses incurred since inception and expected to incur in the future; its dependence on a limited number of products, including the XprESS family of multi-sinus products; physicians’ willingness to change current practices and continue to adopt office-based balloon sinus dilation procedures; inability to maintain adequate levels of reimbursement for the procedures using the company’s products; the impact of competition within the industry; the company’s substantial dependence on a key license agreement; and the company’s ability to establish and maintain intellectual property protection for its products or avoid claims of infringement. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found under the caption “Risk Factors” in the company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission, or SEC, and its other reports filed with the SEC. Entellus Medical undertakes no obligation to update or revise any forward-looking statements, even if subsequent events cause our views to change.

CONTACT: MEDIA CONTACT:
         Leigh Salvo 415-513-1281
         ir@entellusmedical.com
Friday, February 13th, 2015 Uncategorized Comments Off on (ENTL) Announces Release of XprESS(TM) Ultra Multi-Sinus Dilation System

(TUBE) to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Feb. 12, 2015  — TubeMogul, Inc. (Nasdaq:TUBE), a leading enterprise software company for digital branding, today announced that members of the management team will present to the investment community at the following investor conferences:

JMP Securities Technology Conference
Date: Tuesday, March 3, 2015
Time: 12:00 p.m. PT
Location: The Ritz-Carlton, San Francisco, CA
Piper Jaffray Technology, Media & Telecommunications Conference
Date: Wednesday, March 11, 2015
Time: TBD
Location: Le Parker Meridien, New York, NY
Bank of America Merrill Lynch Smid Cap Conference 2015
Date: Tuesday, March 17, 2015
Time: 8:00 a.m. ET
Location: Four Seasons Hotel, Boston, MA

Webcasts will be accessible on the investor relations section of the TubeMogul website (http://investor.tubemogul.com). Archived replays of the webcasts will be available following the live presentations.

About TubeMogul

TubeMogul (Nasdaq:TUBE) is a leading enterprise software company for digital branding. By reducing complexity, improving transparency and leveraging real-time data, our platform enables advertisers to gain greater control of their digital video advertising spend and achieve their brand advertising objectives. TubeMogul was incorporated in 2007 and is based in Emeryville, California with operations in New York, London, Singapore, Tokyo, Sydney, Toronto and offices across the United States.

TubeMogul and the TubeMogul logo are trademarks or registered trademarks of TubeMogul, Inc. in the United States and other countries.

CONTACT: Media Contact:
         David Burch
         press@tubemogul.com

         Investor Relations Contact:
         Alex Wellins
         The Blueshirt Group
         investor@tubemogul.com
Thursday, February 12th, 2015 Uncategorized Comments Off on (TUBE) to Present at Upcoming Investor Conferences

(ZIOP) Announces Exercise of Option to Purchase Additional Shares

BOSTON, Feb. 12, 2015  — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that the underwriters for its recently announced underwritten public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock at a public offering price of $8.75 per share. Gross proceeds to ZIOPHARM from the sale of the additional shares are expected to be approximately $13.1 million before deducting underwriting discounts and commissions and estimated offering expenses payable by ZIOPHARM, bringing the total gross proceeds from the offering to $100.6 million. ZIOPHARM intends to use the net proceeds from the underwritten offering for general corporate and working capital purposes, including clinical development of its pipeline and development of technologies that it has licensed from The University of Texas M.D. Anderson Cancer Center.

J.P. Morgan Securities LLC acted as sole book-running manager for the offering and BMO Capital Markets Corp. acted as senior lead manager. Griffin Securities, Inc., Maxim Group LLC and Mizuho Securities USA Inc. acted as co-managers for the offering. The closing of the sale of the additional shares is expected to occur on or about February 17, 2015, subject to customary closing conditions.

The public offering is being made pursuant to an automatic shelf registration statement on Form S-3ASR previously filed with the Securities and Exchange Commission (the “SEC”), which became automatically effective upon filing.  The offering is being made only by means of a prospectus supplement.  The final prospectus supplement relating to the offering has been filed with the SEC.  Copies of the final prospectus supplement and accompanying prospectus may be obtained at the SEC’s website at www.sec.gov or from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies that can address unmet medical needs through synthetic biology.  Pursuant to an exclusive channel agreement with Intrexon Corporation, ZIOPHARM’s technology platform employs Intrexon’s RheoSwitch Therapeutic System® technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company’s synthetic immuno-oncology programs in collaboration with Intrexon also include chimeric antigen receptor T cell (CAR-T) approaches that they have licensed from The University of Texas M.D. Anderson Cancer Center.

Forward-looking Statements

This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” the negative of these words and similar expressions intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated closing of the sale of the additional shares; the Company’s intended use of proceeds; the progress, timing and results of preclinical and clinical trials involving the Company’s drug candidates; the progress of the Company’s research and development programs; and the Company’s estimates of future revenues and profitability. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: risks related to market conditions and the satisfaction of customary closing conditions related to the underwriters’ exercise of their option, whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-IL-12, DC-RTS-IL-12, palifosfamide, darinaparsin, indibulin, or any of our other therapeutic products will advance further in the pre-clinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-IL-12, DC-RTS-IL-12, palifosfamide, darinaparsin, indibulin, and our other therapeutic products will be successfully marketed if approved; whether any of our other therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; the development of, and our ability to take advantage of, the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

CONTACT: For more information about ZIOPHARM Oncology, contact:

         Lori Ann Occhiogrosso
         Director of Corporate Communication
         ZIOPHARM Oncology, Inc.
         617-259-1987
         locchiogrosso@ziopharm.com

         David Pitts or Eliza Schleifstein
         Argot Partners
         212-600-1902
         david@argotpartners.com
         eliza@argotpartners.com
Thursday, February 12th, 2015 Uncategorized Comments Off on (ZIOP) Announces Exercise of Option to Purchase Additional Shares

(ATNM) Pivotal Trial of Iomab-B Briefing By Principal Investigator Dr. John Pagel Announced

Enthusiastic Interest in Event From Leading Physicians Representing High Volume Transplant Sites Bodes Well for Trial Enrollment

SAN DIEGO, CA–(February 12, 2015) – Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that John Pagel, MD, PhD, Chairman of Actinium’s Scientific Advisory Board and head of the Swedish Cancer Institute Hematologic Malignancies Program in Seattle, along with Dragan Cicic, MD, the Company’s Chief Medical Officer, will discuss the potential of Iomab-B and its upcoming Phase 3 clinical trial with key bone marrow transplanters from major medical centers throughout the US. This drug candidate may address significant unmet medical need in older acute myeloid leukemia (AML) patients.

Leaders in the field of bone marrow transplantation have convened in San Diego this week for a series of annual scientific and organizational conferences. Actinium is hosting individual meetings by appointment with interested clinical investigators and coordinators, to address their questions about the upcoming pivotal trial of Iomab-B. The company and Dr. Pagel are also hosting an educational event for leading clinical investigators on Thursday February 12th, from 6:45-8:00pm at the Marriott Marquis San Diego Marina in the Presidio Room, located at 333 West Harbor Drive in San Diego.

The Company already has confirmed interest in participation in this clinical trial from a number of major academic cancer centers, with highest volumes of bone marrow transplant patients. By informing additional centers about the trial, the Company intends to grow the list of participating sites, in order to maximize the breadth and quality of clinical development experience and support the pace of subject enrollment upon commencement of the Phase 3 trial.

The upcoming Phase 3 study in hematopoietic stem cell transplant (often referred to as bone marrow transplant) will address the serious unmet medical need in older refractory and relapsed AML patients. The Phase 3 trial builds upon a Phase 1/2 trial with Iomab-B in advanced AML and high risk MDS patients which demonstrated successful engraftment by day 28, the achievement of transfusion independent complete response and overall survival of 30% at 1 year and 19% at 2 years.

Principal Investigator Dr. Pagel heads the Swedish Cancer Institute Hematologic Malignancies Program in Seattle. His practice includes caring for patients with acute and chronic leukemias, multiple myeloma, Hodgkin and non-Hodgkin lymphomas, and myelodysplastic syndromes, as well as other myeloproliferative disorders.

Dragan Cicic, MD, Chief Medical Officer of Actinium stated, “We are very pleased with the high level of interest in our upcoming pivotal trial of Iomab-B, a critical step on the path toward potential commercialization of this drug candidate. Based on the strong Phase 1/2 data which demonstrated significant survival and safety benefits when compared to conventional therapy, we remain committed to bringing this potentially lifesaving therapy to market, subject to the successful completion of the Phase 3 trial and FDA approval. We believe Iomab-B addresses a significant unmet need for thousands of elderly AML patients who cannot tolerate current myeloablative conditioning regimens and therefore are unable to receive a potentially curative bone marrow transplant, limiting their life expectancy to only a few months.”

Dr. Pagel commented, “Based on years of direct clinical observation and study, I believe Iomab-B may shift the paradigm in how AML patients are prepared for potentially curative bone marrow transplant, and it could also markedly expand the population eligible for transplant. I believe the Iomab-B Phase 1/2 clinical data demonstrate drug candidate’s potential to become a very important treatment for older relapsed and refractory AML patients, most of whom have ‘nothing on the treatment menu’ to choose from. If successful and approved by the FDA, Iomab-B has the potential to prolong overall survival and improve quality of life in these patients with advanced disease.”

About Bone Marrow Transplant:

Bone marrow transplants (BMT) are most commonly used to treat leukemia and lymphoma, conditions incurred when a blood or immune cell, respectively, becomes cancerous and proliferates. Together, these diseases account for some 50,000 to 75,000 new cases annually in the United States. BMT involves first clearing a patient’s body of his or her own immune cells and then transplanting bone marrow, the source of all blood- and immune-forming cells, from a tissue-matched donor. The new cells, which are free of cancer, repopulate the patient’s bone marrow and eventually give rise to a functioning set of blood and immune cells, providing a lifelong cure. BMT offers the chance of a “curative” outcome (2+ year survival), and therefore can play a central role in the treatment of AML. The impact of BMT on AML continues to increase with AML being the most common and fastest growing indication for allogeneic BMT, comprising 25% to 30% of all BMT recipients. There are currently over 100,000 BMT survivors across all indications and this number is expected to increase to 250,000 by 2020 and 500,000 by 2030, with 25% of them over age 60.

About Iomab-B

Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin’s disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in such statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.
Evan Smith, CFA
VP Investor Relations and Finance
(646) 840-5442
esmith@actiniumpharma.com

Thursday, February 12th, 2015 Uncategorized Comments Off on (ATNM) Pivotal Trial of Iomab-B Briefing By Principal Investigator Dr. John Pagel Announced

(SGMO) Presents Data At 11th Annual WorldSymposium On In Vivo Protein Replacement Platform

Novel ZFN Genome Editing Approach Results in Sustained Levels of Enzymes Associated with Hunter, Hurler and Gaucher Syndromes

RICHMOND, Calif., Feb. 12, 2015  — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the presentation of preclinical data from its In Vivo Protein Replacement Platform (IVPRP) program for the development of proprietary ZFP Therapeutics® for the potential cure of lysosomal storage disorders (LSDs). The study was presented at the WORLDSymposium 2015 Meeting, a multidisciplinary forum presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases, which is being held in Orlando, Florida, from February 9-13, 2015. The data were generated by Sangamo scientists and their collaborators at the University of Minnesota and University of Massachusetts Medical School.

Data presented at WORLDSymposium 2015 demonstrate that Sangamo’s zinc finger nuclease (ZFN) genome editing technology can specifically integrate into the albumin locus of normal mice, human genes encoding functional enzymes that are defective in the LSDs Hunter, Hurler and Gaucher syndromes. Following ZFN-mediated genome editing, robust levels of protein expression were observed in the liver, blood plasma and spleen, leading to increases in enzymatic activity of up to 100-fold. Furthermore, elevated enzyme activity in the blood plasma was sustained over the course of the two month study.

“For lysosomal storage diseases, the population in greatest need is small children. To intervene in the very young and achieve a long-lasting therapeutic effect from a single administration demands stability of enzyme expression over the lifetime of the patient. It is precisely this ability to drive a permanent change at the DNA level that is enabled by our ZFN-driven in vivo protein replacement strategy,” stated Philip Gregory, D. Phil., Sangamo’s senior vice president of research and chief scientific officer. “These data show substantial increases in the activity of the target enzymes in the liver, blood plasma, and spleen, consistent with the effective production, secretion, and importantly, uptake, of the functional therapeutic proteins by other cells and tissues of the body. Thus, by harnessing a tiny fraction of the liver’s powerful albumin promoter and synthesis pathway, we are able to produce sustainable levels of LSD enzymes for the potentially long-term treatment of various lysosomal storage disorders.”

“These data highlight that our proprietary ZFN-enabled genome editing technology can generate broadly applicable and disruptive approaches for the potential cure of numerous monogenic diseases including LSDs,” stated Edward Lanphier, Sangamo’s president and CEO. “Our goal is to move our Hunter and Hurler ZFN Therapeutic programs through IND-enabling studies in 2015.”

About Lysosomal Storage Disorders
Lysosomal storage disorders are a heterogeneous group of inherited genetic disorders, including Hunter, Hurler, and Gaucher syndromes, that are caused by defects in genes that encode enzymes that break down and eliminate unwanted substances in the cells of the body. These enzymes are found in structures called lysosomes which act as recycling sites in cells, breaking down unwanted material into simple products for the cell to reuse. A defect in a lysosomal enzyme leads to the accumulation of toxic levels of the substance that the enzyme would normally break-down and results in cell damage which can lead to serious health consequences.

There are nearly 50 LSDs altogether and they may affect different parts of the body, including the skeleton, brain, skin, heart and CNS. Currently, there are no cures for LSDs, and treatments have not yet been developed for many of these diseases. For certain disorders, including Hunter and Hurler syndromes, costly enzyme replacement therapies (ERTs) are available, but require frequent administration in order to be effective. Over time, patients may also develop an immunogenic response to the administered protein, rendering the ERT less efficacious.

Background on Sangamo’s IVPRP Approach
The IVPRP approach makes use of the albumin gene locus, a highly expressing and liver-specific genomic “safe-harbor site”, that can be edited with zinc finger nucleases (ZFNs) to accept and express any therapeutic gene. The platform enables the patient’s liver to permanently produce therapeutic levels of a corrective protein product such as factor VIII or IX to treat hemophilia, or replacement enzymes to treat lysosomal storage disorders. With such a large capacity for protein production (approximately 15g/day of albumin), which is in excess of the body’s requirements, targeting and co-opting only a very small percentage of the albumin gene’s capacity is sufficient to produce the needed replacement protein at therapeutically relevant levels with no significant effect on albumin production.

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has clinical stage programs to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728-T), beta-thalassemia (SB-BCLmR-HSPC), and NGF-AAV for Alzheimer’s disease (CERE-110). Sangamo’s other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company’s website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references relating to research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo’s ZFP technology platform; the potential of Sangamo’s ZFP technology to treat LSDs, Hunter, Hurler and Gaucher syndromes and the safety of the approach of using ZFP-mediated genome editing in vivo; the expected IND studies for Hunter and Hurler programs; and the applicability of Sangamo’s ZFP technology in monogenic diseases. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the safety, tolerability and efficacy of ZFNs and ZFP TFs, technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo’s public filings with the Securities and Exchange Commission, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

Thursday, February 12th, 2015 Uncategorized Comments Off on (SGMO) Presents Data At 11th Annual WorldSymposium On In Vivo Protein Replacement Platform

(CVV) Reports $45 Million in 2014 Orders

CVD Equipment Corporation (Nasdaq: CVV) , a leading provider of standard and custom chemical vapor deposition systems, today announced that it received in excess of $45 Million in orders during 2014.

Leonard Rosenbaum, President and Chief Executive Officer stated, “CVD is continuing to experience high levels of orders and quote activity. We anticipate that this trend will continue into 2016 and beyond as orders for production and research equipment, including equipment for aerospace, medical devices, and nano materials, are continuing to drive our business forward. Our new facility is humming with activity, we have increased our production personnel by 13% over the past four months and our crew is working diligently to convert these orders into revenue.”

About CVD Equipment Corporation

CVD Equipment Corporation (NASDAQ: CVV) is a designer and manufacturer of custom and standard state-of-the-art equipment used in the development, design and manufacture of advanced electronic components, materials and coatings for research and industrial applications. CVD offers a broad range of chemical vapor deposition, gas control, and other equipment that is used by customers to research, design and manufacture semiconductors, solar cells, graphene, carbon nanotubes, nanowires, LEDs, MEMS, smart glass coatings, batteries, ultra capacitors, medical coatings, industrial coatings and equipment for surface mounting of printed circuit components. CVD’s application laboratory focuses on higher efficiency nano and nano to macro material manufacturing for a wide variety of growth markets, which are marketed through our wholly owned subsidiary CVD Materials Corporation.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by CVD Equipment Corporation) contains statements that are forward-looking. All statements other than statements of historical fact are hereby identified as “forward-looking statements, “as such term is defined in Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward looking information involves a number of known and unknown risks and uncertainties that could cause actual results to differ materially from those discussed or anticipated by management. Potential risks and uncertainties include, among other factors, conditions, success of CVD Equipment Corporation’s growth and sales strategies, the possibility of customer changes in delivery schedules, cancellation of orders, potential delays in product shipments, delays in obtaining inventory parts from suppliers and failure to satisfy customer acceptance requirements.

CVD Equipment Corporation
Karen Hamberg, 631-981-7081
Fax: 631-981-7095
investorrelations@CVDequipment.com
Sales@CVDequipment.com

Thursday, February 12th, 2015 Uncategorized Comments Off on (CVV) Reports $45 Million in 2014 Orders

(HART) Pricing of Public Offering of Common & Series B Convertible Preferred Stock

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced the pricing of its previously announced underwritten public offering. HART is offering 1,800,000 registered shares of its common stock at a price to the public of $1.75 per share, and 695,857 registered shares of its Series B Convertible Preferred Stock (“Series B”) at a price to the public of $8.75 per share, for expected gross proceeds of approximately $9.2 million. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. In connection with the offering, HART has also granted the underwriter a 30-day option to purchase up to an additional 270,000 shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes.

The offering is expected to settle and close on February 18, 2015, subject to the satisfaction or waiver of customary closing conditions. National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (OTCBB: NHLD) is acting as sole book runner in the offering and Summer Street Research Partners is acting as co- manager for the offering.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-200926), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on December 29, 2014. A final prospectus supplement describing the terms of the offering will be filed with the SEC. Any offer will be made only by means of a prospectus supplement and accompanying base prospectus forming a part of the effective registration statement. Before investing, you should read the prospectus supplement and the accompanying base prospectus, and other documents that HART has filed or will file with the SEC, for information about HART and this offering.

Once filed, copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting National Securities Corporation at the following address:

National Securities Corporation
410 Park Ave, 14th Floor
New York, NY 10022
Attn: Kim Addarich
Telephone: (212) 417-8164
Email: prospectusrequest@nationalsecurities.com

Investors may also obtain these documents for no charge by visiting the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of HART and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our HART-Trachea technology has been used in six human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements in this press release include, but are not limited to, HART’s expectations regarding the completion, timing and size of its proposed public offering, whether expressed or implied, statements relating to the success with respect to any regulatory filings and approval pertaining to the HART-Trachea or any other HART products, by the FDA, MHRA, European Medicines Agency, or otherwise, which such filings or approvals may not be made or obtained on a timely basis or at all, and success with respect to clinical trials, commercialization efforts and marketing approvals of HART’s products, including our HART-Trachea product, which such success or approvals may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, HART’s ability to complete the offering, as well as the actual size and terms of the offering and its ability to raise additional capital, as well those factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. HART expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Harvard Apparatus Regenerative Technology, Inc.:
David Green, 774-233-7320
President and CEO
dgreen@HARTregen.com
or
Tom McNaughton, 774-233-7321
CFO
tmcnaughton@HARTregen.com

Thursday, February 12th, 2015 Uncategorized Comments Off on (HART) Pricing of Public Offering of Common & Series B Convertible Preferred Stock

(AREX) Announces Record Annual Production and Proved Reserves

Approach Resources Inc. (NASDAQ:AREX) today reported estimated fourth quarter and full-year 2014 production and reserves.

Production Highlights

  • Fourth quarter production was 15.1 MBoe/d, a 34% increase over the prior-year quarter
  • Full-year 2014 production was 5,049 MBoe, a 47% increase over the prior year
  • Oil production was 2,024 MBbls, a 40% increase over the prior year
  • Oil production represented 40% of total production for full-year 2014
  • Drilled 68 horizontal wells and placed 64 horizontal wells on production
  • 2014 capital expenditures of $393.5 million

Proved Reserves Highlights

  • Year-end 2014 proved reserves grew to 146.2 MMBoe, a 27% increase over the prior year
  • PV-10 (non-GAAP) was $1.4 billion, a 25% increase over the prior year

Management Comment

Ross Craft, Approach’s Chairman and CEO commented, “At the beginning of 2014 we set an ambitious goal of achieving a 40% annual production growth rate, while maintaining one of the lowest drilling and completion cost structures in the Permian Basin. Now with 12 months behind us, I am very pleased with the operational performance of our team. Not only were we able to beat our original production goal and deliver a 47% growth in production, but even more importantly, we were able to do that while controlling our capital costs, which came in below our original $400 million budget.

Looking ahead to 2015, our industry is presented with a different set of challenges, given the significant change in commodity prices. We continue to conservatively manage our balance sheet, and we remain flexible on our capital spending budget, particularly as we take proactive steps to further reduce our cost structure and enhance drilling economics. Most importantly, we have no near-term debt maturities, and our liquidity position is strong, providing the ability to weather a prolonged downturn in commodity prices and to take advantage of opportunities that may become available.”

Estimated Fourth Quarter and Full-Year 2014 Production

Estimated fourth quarter 2014 production totaled 1,390 MBoe (15.1 MBoe/d), a 34% increase over fourth quarter 2013 and a 6.4% increase over third quarter 2014. Estimated oil production for fourth quarter 2014 increased 14% compared to fourth quarter 2013 and 7.1% from third quarter 2014.

Estimated full-year 2014 production totaled 5,049 MBoe (13.8 MBoe/d), a 47% increase over 2013. Oil production for 2014 increased 40% compared to 2013.

Three Months Ended Twelve Months Ended
December 31, December 31,
2014 2013 2014 2013
Production:
Oil (MBbls) 542 475 2,024 1,444
NGLs (MBbls) 404 268 1,461 951
Gas (MMcf) 2,656 1,784 9,383 6,177
Total (MBoe) 1,390 1,041 5,049 3,424
Total (MBoe/d) 15.1 11.3 13.8 9.4
% Oil 39% 46% 40% 42%

2014 Estimated Proved Reserves and Costs Incurred

Year-end 2014 proved reserves totaled 146.2 MMBoe, up 27% from year-end 2013 proved reserves of 114.7 MMBoe. Our proved oil reserves increased 20% to 55.3 MMBbls, compared to year-end 2013 proved oil reserves of 46.1 MMBbls. Year-end 2014 proved reserves were 38% oil, 28% NGLs and 34% natural gas. Proved developed reserves represent approximately 41% of total year-end 2014 proved reserves, up from 39% at year-end 2013.

Preliminary, unaudited costs incurred during 2014 totaled $ 393.5 million and included $364 million for drilling and completion activities, $24.9 million for infrastructure projects and other equipment and $4.6 million for acreage acquisitions and lease extensions.

Conference Call Scheduled for Thursday, February 26, 2015

The Company plans to announce fourth quarter and full-year 2014 financial and operational results on Wednesday, February 25, 2015, after close of trading. In addition, the Company plans to host a conference call on Thursday, February 26, 2014, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time) to discuss fourth quarter and full-year 2014 financial and operational results. Those wishing to listen to the conference call, may do so by visiting the Events page under the Investor Relations section of the Company’s website, www.approachresources.com, or by phone:

Dial in: (877) 201-0168
Intl. dial in: (647) 788-4901
Passcode: Approach/76119425

A replay of the call will be available on the Company’s website or by dialing:

Dial in: (855) 859-2056
Passcode: 76119425

Supplemental Non-GAAP Financial and Other Measures

PV-10

The present value of our proved reserves, discounted at 10% (“PV-10”), was estimated at $1.4 billion at December 31, 2014, and was calculated based on the first-of-the-month, 12-month average prices for oil, NGLs and gas, of $94.56 per Bbl of oil, $31.50 per Bbl of NGLs and $4.55 per MMBtu of natural gas.

PV-10 is our estimate of the present value of future net revenues from proved oil and gas reserves after deducting estimated production and ad valorem taxes, future capital costs and operating expenses, but before deducting any estimates of future income taxes. The estimated future net revenues are discounted at an annual rate of 10% to determine their “present value.” We believe PV-10 to be an important measure for evaluating the relative significance of our oil and gas properties and that the presentation of the non-GAAP financial measure of PV-10 provides useful information to investors because it is widely used by professional analysts and investors in evaluating oil and gas companies. Because there are many unique factors that can impact an individual company when estimating the amount of future income taxes to be paid, we believe the use of a pre-tax measure is valuable for evaluating the Company. We believe that PV-10 is a financial measure routinely used and calculated similarly by other companies in the oil and gas industry.

The Company has not provided a reconciliation of its PV-10 to our standardized measure of discounted future net cash flows, the most directly comparable measure calculated and presented in accordance with GAAP, in this release because final income tax information for 2014 is not yet available. The Company will provide its customary reconciliation of PV-10 to standardized measure in its forthcoming Form 10-K for the year ended December 31, 2014, to be filed with the SEC.

About Approach Resources

Approach Resources Inc. is an independent energy company focused on the exploration, development, production and acquisition of unconventional oil and gas reserves in the Midland Basin of the greater Permian Basin in West Texas. For more information about the Company, please visit www.approachresources.com. Please note that the Company routinely posts important information about the Company under the Investor Relations section of its website.

Forward-Looking and Cautionary Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by the Company based on management’s experience, perception of historical trends and technical analyses, current conditions, anticipated future developments and other factors believed to be appropriate and reasonable by management. When used in this press release, the words “will,” “potential,” “believe,” “estimate,” “intend,” “expect,” “may,” “should,” “anticipate,” “could,” “plan,” “predict,” “project,” “profile,” “model” or their negatives, other similar expressions or the statements that include those words, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Further information on such assumptions, risks and uncertainties is available in the Company’s Securities and Exchange Commission (“SEC”) filings. The Company’s SEC filings are available on the Company’s website at www.approachresources.com. Any forward-looking statement speaks only as of the date on which such statement is made and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Approach Resources Inc.
Sergei Krylov, 817.989.9000
Executive Vice President & Chief Financial Officer
ir@approachresources.com

Wednesday, February 11th, 2015 Uncategorized Comments Off on (AREX) Announces Record Annual Production and Proved Reserves

(NVGN) Lodges Key Super-benzopyran Patent

SYDNEY, Feb. 11, 2015  — Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the lodgement of final specifications of a patent that covers the Company’s first family of super-benzopyran compounds that to date has yielded leading drug candidates TRXE-002, TRXE-009 and TRXE-0025.

Super-benzopyrans represent a new chemical structure of increasing complexity and diversity. Based on the degree of that complexity, Novogen chemists have identified at least 6 patent families of related compounds. The final patent specifications just lodged represent the first of those families, with some hundreds of molecules designed and manufactured over the past 12 months. The focus with this particular family of compounds has been their ability to kill cancer stem cells. The underlying pharmacophore responsible for this activity has been identified and forms a key aspect of the patent.

Work is progressing on the remaining 5 potential patent families to determine the underlying pharmacophores relevant to various activities including the promotion of neurogenesis, to the promotion of functionality of stem cells with genetic abnormalities, and to the treatment of lysosomal storage diseases. Once those potential patent families have been reduced to practice, then the appropriate patents will be lodged.

Andrew Heaton PhD, Novogen Group Vice-President of Drug Discovery and Manufacture, said, “The last 12 months has been a highly productive time of reducing our super-benzopyran drug discovery program to practice, so allowing this PCT final specification to be lodged. Happily, we also are seeing these drugs successfully come through their large-scale manufacturing process ahead of a number of clinical trials over the next 12 months. We have not hit any manufacturing hurdles, confirming the simpler manufacturing process that is a key part of the patent.”

Graham Kelly PhD, Novogen Group CEO, said, “Andrew’s drug discovery team has delivered an exciting opportunity to the Company. These new families of not previously seen compounds are proving an extraordinarily rich source of potential new therapeutics. It is remarkable that the same underlying molecular structure can yield compounds of such diverse biological activity. This pleiotropy is what makes this family of compounds so valuable.”

“The lodgement of this patent also opens the way for our collaborators to present data for conference presentations and publications where disclosure of molecular structure is required,” Kelly added.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell’s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our website: www.novogen.com

For more information please contact:

Corporate ContactDr. Graham Kelly

Executive Chairman & CEO

Novogen Group

Graham.Kelly@novogen.com

+61 (0) 2 9472 4100

Media EnquiriesCristyn Humphreys

Chief Operating Officer

Novogen Group

Cristyn.Humphreys@novogen.com

+61 (0) 2 9472 4111

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as “expects,” “appear,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “should,” “would,”  “may,” “target,”  “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to events that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to the Company’s two proprietary technology platforms, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Wednesday, February 11th, 2015 Uncategorized Comments Off on (NVGN) Lodges Key Super-benzopyran Patent

(CDTI) Appoints International Automotive Industry Veteran Dr. Till Becker to Board

OXNARD, Calif., Feb. 11, 2015  — Clean Diesel Technologies, Inc. (Nasdaq:CDTI) (“CDTi” or “the Company”), a leader in advanced emission control technology, appointed Dr. Till Becker to the Company’s Board of Directors, effective February 9, 2015, increasing the number of directors to six. Dr. Becker will serve on the Technology Committee.

“Dr. Becker’s extensive international automotive leadership experience will be a valuable resource during CDTi’s transition from an emissions control manufacturer to an advanced materials technology company,” said Chairman Charles Engles, Ph.D. “CDTi plans to broadly commercialize its new advanced low- and zero-platinum group metal technologies, featuring its breakthrough Spinel™ technology.  Dr. Becker’s in-depth understanding of the global automotive supply chain and his contacts there will help guide the Company to the next stage of its growth and evolution. The Board joins me in welcoming him to CDTi.”

“CDTi’s Spinel™ technology platform represents an important breakthrough in clean air solutions,” Dr. Becker stated. “I look forward to working with the Company’s executive leadership team and Board of Directors to realize the potential of the Company’s advanced materials technology strategy and drive CDTi toward future success.”

Dr. Becker has more than 25 years of international experience in the automotive, consumer goods and energy industries and an extensive background in corporate restructuring and M&A transactions. He was at Daimler AG from 1987 to 2006, where he ran major international subsidiaries and served as Executive Vice President of the parent company. He served as Chairman and CEO of Daimler Northeast Asia, Mercedes-Benz Türk A.S., Istanbul, Mercedes-Benz India Pvt. Ltd. and Mercedes-Benz Portugal SA. In 2013, Dr. Becker served as CEO of Hess AG, a provider of world-class lighting systems, where he implemented a successful restructuring plan that led to the company’s sale. From 2010 to 2011, he served as interim CEO of MPS Micropaint Holding AS, an international distributor of premium spot repair systems for small paint damage to automobiles and as an advisor to RealEyes GmbH, a three-dimensional display imaging firm. From 2008 to 2010, Dr. Becker served as an advisor to Capital Dynamics Ltd., an independent, global asset management firm that invests in private equity and clean energy infrastructure.   Dr. Becker currently serves as a Senior Advisor at Global Board Room Advisors, an Asia-focused M&A consulting firm which he co-founded in 2011. He also serves as Senior Advisor to Holland Private Equity Growth Capital, an investment firm focused on growth-stage investments in small to mid-market technology companies in the Benelux and Germany, and Senior Consultant to Artris Management Ltd., a European consulting and M&A company. Dr. Becker holds a law degree from the University of Münster.

About CDTi

CDTi manufactures and distributes vehicle emissions control products that leverage its advanced materials technology. CDTi utilizes its proprietary patented Mixed Phase Catalyst (MPC®) technology and other related technologies to provide high-value sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road combustion engine systems. Reflecting its continued focus on innovation, CDTi is developing and commercializing proprietary advanced low-platinum group metal (PGM) catalysts including synergized-PGM (SPGM™), as well as zero-PGM (ZPGM™) catalysts. CDTi is headquartered in Oxnard, California and has operations in the U.K., Canada, France, Japan and Sweden. For more information, please visit www.cdti.com.

Forward-Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact should be considered forward-looking statements. You can identify these forward-looking statements by the use of the words “believes”, “expects”, “anticipates”, “plans”, “may”, “will”, “would”, “intends”, “estimates”, and other similar expressions, whether in the negative or affirmative. Forward-looking statements are based on a series of expectations, assumptions, estimates and projections which involve substantial uncertainty and risk. In this document, the Company includes forward looking statements regarding (a) its growth, future success, strategies and focus on innovation; (b) the effect Dr. Becker may have on the Company; (c) its transition to an advanced materials technology company; (d) its plans to broadly commercialize its new technologies; (e) the benefits of its technology; (f) the achievement of intended results; and (g) its ability to develop and commercialize proprietary advanced low- or zero-PGM catalysts. In general, actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including, but not limited, to (i) any inability by CDTi to (1) reduce costs; (2) increase sales; (3) realize the benefits of investments; (4) obtain sufficient funding; (5) realign its strategic path; (6) execute its strategic priorities; (7) commercialize its technology due to agreements with third parties; (8) protect its intellectual property; (9) obtain verifications, approvals or market acceptance of its products or technology; (10) attract or retain qualified personnel; or (11) achieve anticipated results; (ii) changes in or lack of enforcement of or funding for emissions programs, regulations or standards; (iii) competitive conditions; (iv) prices of PGM and rare earth metals; (v) intellectual property infringement claims by third parties; (vi) supply or delivery interruptions, limitations or failures; (vii) the loss of one or more major customers; (viii) product malfunctions, design failures or the inability to meet emissions control standards; and (ix) other risks and uncertainties discussed or referenced in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. In addition, any forward-looking statements represent the Company’s estimates only as of the date of such statements and should not be relied upon as representing the Company’s estimates as of any subsequent date. The Company specifically disclaims any obligation to update forward-looking statements. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

CONTACT:  Becky Herrick or Cathy Mattison
          LHA (IR Agency)
          +1 415 433 3777
          bherrick@lhai.com
          cmattison@lhai.com
Wednesday, February 11th, 2015 Uncategorized Comments Off on (CDTI) Appoints International Automotive Industry Veteran Dr. Till Becker to Board

(DGLY) Expands Commercial Customer Base for Cloud-Based FleetVU Manager Software

Recurring Revenue Cloud Solution Rapidly Growing in Commercial Markets

LENEXA, KS–(Feb 11, 2015) – Digital Ally, Inc. (NASDAQ: DGLY), which develops, manufactures and markets advanced video surveillance products for law enforcement, homeland security and commercial applications, today announced that demand for its FleetVU Manager software solution continues to expand among commercial fleet operators. Recent orders have been received from operators of EMS vehicles (ambulances), taxis and small-bus fleets.

FleetVU Manager is our revolutionary, web-based fleet tracking and monitoring software that features and manages video, captured by Digital Ally’s Video Event Data Recorders, of incidents that require attention, such as accidents,” stated Stanton E. Ross, the Company’s Chief Executive Officer. “The developed software solution features Digital Ally’s cloud-based web portal, which utilizes many of the features of our VUVault.NET law-enforcement cloud-based storage solution. To date, we have booked orders for over 360 DVM-250 Event Recorders and 58 Asset Tracking Units that will generate recurring revenue from the cloud over the next several years. The simplicity and security of the cloud is rapidly growing and complementing our server-based platforms in a number of commercial markets.”

“We have been very pleased with the enthusiastic reception that FleetVU Manager has received among operators of ambulance fleets, and we have recently expanded our marketing for the software solution to include taxis and operators of mini-bus fleets, including off-airport parking buses,” continued Ross.

Digital Ally’s FleetVU Manager is a cost-effective cloud telematics and video storage system that offers fleet incident video management and reporting capabilities through an informative and user-friendly interface that can be enhanced with future, customizable live asset tracking modules.

Features of the FleetVU Manager include:

  • Real-time alerts that allow management to be connected 24 hours a day, from any location.
  • Customizable auto-delete feature maintains cloud data at a manageable size.
  • Cloud has ample memory with adequate space to record from additional cameras (e.g., rear view, PTO switches, cargo department doors).
  • Incorporates asset tracking units and video into the same cloud platform.
  • Integrates real-time alerts into pre- and post-operation inspections, thereby maximizing driver safety and minimizing maintenance delays.
  • Manages fleet drivers through proprietary algorithm and fleet scoring system.
  • Available with three-year cloud service and three-year warranty.

“The cloud is simple to maintain, budget-friendly and provides off-site backup,” noted John Rumage, Director of Commercial Sales at Digital Ally, Inc. “FleetVU Manager users can securely access data from anywhere with an Internet connection on a variety of devices, whether desktop, laptop, smartphone or tablet. This lets fleet managers operate in real-time, regardless of location, thereby enhancing the cost-effectiveness of fleet operations. It also upgrades automatically, allowing users to benefit from all the newest capabilities on the most current operating systems.”

In addition to cloud storage, FleetVU Manager provides an efficient interface that provides for the analysis of fleet performance and automated driver behavior statistics, customizable reporting, access to detailed driver and vehicle information, wireless configuration and firmware updating, functionality checks, alert triggers and geo-fencing, and the ability to review incident video, causality data, and interactive route maps.

About Digital Ally, Inc.

Digital Ally, Inc. develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial applications. The Company’s primary focus is digital video imaging and storage. For additional information, visit www.digitalallyinc.com.

The Company is headquartered in Lenexa, Kansas, and its shares are traded on The NASDAQ Capital Market under the symbol “DGLY”.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: whether the FleetVU Manager will assist the Company in increase sales of its commercial products and the revenues of its commercial division; the Company’s ability to deliver its new product offerings, including the FleetVU Manager, as scheduled and have them perform as planned; whether the interest shown in the Company’s newer products, including the FleetVU Manager, will translate into sales; competition from larger, more established companies with far greater economic and human resources; its ability to attract and retain customers and quality employees; the effect of changing economic conditions; and changes in government regulations, tax rates and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company’s disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “projects”, “should”, or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in its annual report on Form 10-K for the year ended December 31, 2013 and quarterly report on Form 10-Q for the three and nine months ended September 30, 2014, as filed with the Securities and Exchange Commission. 

For Additional Information, Please Contact:
Stanton E. Ross
CEO
(913) 814-7774

or

RJ Falkner & Company, Inc.
Investor Relations Counsel
(800) 377-9893
info@rjfalkner.com

Wednesday, February 11th, 2015 Uncategorized Comments Off on (DGLY) Expands Commercial Customer Base for Cloud-Based FleetVU Manager Software
Top Small Cap Market News